WO2005066214A1 - ヒアルロン酸誘導体及びそれを含む薬剤 - Google Patents
ヒアルロン酸誘導体及びそれを含む薬剤 Download PDFInfo
- Publication number
- WO2005066214A1 WO2005066214A1 PCT/JP2005/000125 JP2005000125W WO2005066214A1 WO 2005066214 A1 WO2005066214 A1 WO 2005066214A1 JP 2005000125 W JP2005000125 W JP 2005000125W WO 2005066214 A1 WO2005066214 A1 WO 2005066214A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- hyaluronic acid
- solution
- spacer
- compound
- acid derivative
- Prior art date
Links
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical class CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 title claims abstract description 256
- 239000003814 drug Substances 0.000 title claims description 64
- 229940079593 drug Drugs 0.000 title claims description 48
- 150000001875 compounds Chemical class 0.000 claims abstract description 158
- 229920002674 hyaluronan Polymers 0.000 claims abstract description 147
- 229960003160 hyaluronic acid Drugs 0.000 claims abstract description 146
- 230000003110 anti-inflammatory effect Effects 0.000 claims abstract description 76
- 125000006850 spacer group Chemical group 0.000 claims abstract description 72
- 238000000034 method Methods 0.000 claims abstract description 45
- 239000000243 solution Substances 0.000 claims description 238
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 109
- -1 fuerbinac Chemical compound 0.000 claims description 78
- 238000006243 chemical reaction Methods 0.000 claims description 62
- 229960001259 diclofenac Drugs 0.000 claims description 62
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 claims description 62
- 239000002953 phosphate buffered saline Substances 0.000 claims description 61
- DCOPUUMXTXDBNB-UHFFFAOYSA-N diclofenac Chemical compound OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl DCOPUUMXTXDBNB-UHFFFAOYSA-N 0.000 claims description 54
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 42
- 238000002347 injection Methods 0.000 claims description 40
- 239000007924 injection Substances 0.000 claims description 40
- 239000003795 chemical substances by application Substances 0.000 claims description 30
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 27
- 125000001424 substituent group Chemical group 0.000 claims description 21
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 20
- 208000036487 Arthropathies Diseases 0.000 claims description 19
- 208000012659 Joint disease Diseases 0.000 claims description 19
- 125000000217 alkyl group Chemical group 0.000 claims description 19
- 239000012736 aqueous medium Substances 0.000 claims description 18
- 125000000524 functional group Chemical group 0.000 claims description 17
- 238000001727 in vivo Methods 0.000 claims description 17
- 230000003637 steroidlike Effects 0.000 claims description 15
- 239000011148 porous material Substances 0.000 claims description 14
- 125000004432 carbon atom Chemical group C* 0.000 claims description 13
- 229960005293 etodolac Drugs 0.000 claims description 13
- 229960002390 flurbiprofen Drugs 0.000 claims description 13
- SYTBZMRGLBWNTM-UHFFFAOYSA-N flurbiprofen Chemical compound FC1=CC(C(C(O)=O)C)=CC=C1C1=CC=CC=C1 SYTBZMRGLBWNTM-UHFFFAOYSA-N 0.000 claims description 13
- 229960003464 mefenamic acid Drugs 0.000 claims description 13
- 125000003545 alkoxy group Chemical group 0.000 claims description 12
- 230000000202 analgesic effect Effects 0.000 claims description 12
- 229960001395 fenbufen Drugs 0.000 claims description 12
- 125000005843 halogen group Chemical group 0.000 claims description 12
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 claims description 12
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 claims description 11
- 239000002253 acid Substances 0.000 claims description 11
- 125000003277 amino group Chemical group 0.000 claims description 11
- 229960001680 ibuprofen Drugs 0.000 claims description 11
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 10
- XFBVBWWRPKNWHW-UHFFFAOYSA-N etodolac Chemical compound C1COC(CC)(CC(O)=O)C2=N[C]3C(CC)=CC=CC3=C21 XFBVBWWRPKNWHW-UHFFFAOYSA-N 0.000 claims description 10
- CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 claims description 10
- 239000002504 physiological saline solution Substances 0.000 claims description 10
- 239000004480 active ingredient Substances 0.000 claims description 9
- 239000003435 antirheumatic agent Substances 0.000 claims description 9
- 201000010099 disease Diseases 0.000 claims description 9
- 238000001914 filtration Methods 0.000 claims description 9
- 230000003356 anti-rheumatic effect Effects 0.000 claims description 8
- 238000004519 manufacturing process Methods 0.000 claims description 8
- HYYBABOKPJLUIN-UHFFFAOYSA-N mefenamic acid Chemical compound CC1=CC=CC(NC=2C(=CC=CC=2)C(O)=O)=C1C HYYBABOKPJLUIN-UHFFFAOYSA-N 0.000 claims description 8
- 239000008215 water for injection Substances 0.000 claims description 8
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 claims description 7
- 229960001138 acetylsalicylic acid Drugs 0.000 claims description 7
- 150000001413 amino acids Chemical class 0.000 claims description 7
- ZPAKPRAICRBAOD-UHFFFAOYSA-N fenbufen Chemical compound C1=CC(C(=O)CCC(=O)O)=CC=C1C1=CC=CC=C1 ZPAKPRAICRBAOD-UHFFFAOYSA-N 0.000 claims description 7
- 239000000470 constituent Substances 0.000 claims description 6
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 claims description 6
- 229960004889 salicylic acid Drugs 0.000 claims description 6
- ZRVUJXDFFKFLMG-UHFFFAOYSA-N Meloxicam Chemical compound OC=1C2=CC=CC=C2S(=O)(=O)N(C)C=1C(=O)NC1=NC=C(C)S1 ZRVUJXDFFKFLMG-UHFFFAOYSA-N 0.000 claims description 5
- 229960004369 flufenamic acid Drugs 0.000 claims description 5
- LPEPZBJOKDYZAD-UHFFFAOYSA-N flufenamic acid Chemical compound OC(=O)C1=CC=CC=C1NC1=CC=CC(C(F)(F)F)=C1 LPEPZBJOKDYZAD-UHFFFAOYSA-N 0.000 claims description 5
- 229960000905 indomethacin Drugs 0.000 claims description 5
- OXROWJKCGCOJDO-JLHYYAGUSA-N lornoxicam Chemical compound O=C1C=2SC(Cl)=CC=2S(=O)(=O)N(C)\C1=C(\O)NC1=CC=CC=N1 OXROWJKCGCOJDO-JLHYYAGUSA-N 0.000 claims description 5
- 229960002202 lornoxicam Drugs 0.000 claims description 5
- 229960002373 loxoprofen Drugs 0.000 claims description 5
- 229960001929 meloxicam Drugs 0.000 claims description 5
- 229960002739 oxaprozin Drugs 0.000 claims description 5
- OFPXSFXSNFPTHF-UHFFFAOYSA-N oxaprozin Chemical compound O1C(CCC(=O)O)=NC(C=2C=CC=CC=2)=C1C1=CC=CC=C1 OFPXSFXSNFPTHF-UHFFFAOYSA-N 0.000 claims description 5
- 238000007911 parenteral administration Methods 0.000 claims description 5
- 229960002702 piroxicam Drugs 0.000 claims description 5
- QYSPLQLAKJAUJT-UHFFFAOYSA-N piroxicam Chemical compound OC=1C2=CC=CC=C2S(=O)(=O)N(C)C=1C(=O)NC1=CC=CC=N1 QYSPLQLAKJAUJT-UHFFFAOYSA-N 0.000 claims description 5
- 229960000894 sulindac Drugs 0.000 claims description 5
- MLKXDPUZXIRXEP-MFOYZWKCSA-N sulindac Chemical compound CC1=C(CC(O)=O)C2=CC(F)=CC=C2\C1=C/C1=CC=C(S(C)=O)C=C1 MLKXDPUZXIRXEP-MFOYZWKCSA-N 0.000 claims description 5
- 229960002871 tenoxicam Drugs 0.000 claims description 5
- LZNWYQJJBLGYLT-UHFFFAOYSA-N tenoxicam Chemical compound OC=1C=2SC=CC=2S(=O)(=O)N(C)C=1C(=O)NC1=CC=CC=N1 LZNWYQJJBLGYLT-UHFFFAOYSA-N 0.000 claims description 5
- 229960001017 tolmetin Drugs 0.000 claims description 5
- UPSPUYADGBWSHF-UHFFFAOYSA-N tolmetin Chemical compound C1=CC(C)=CC=C1C(=O)C1=CC=C(CC(O)=O)N1C UPSPUYADGBWSHF-UHFFFAOYSA-N 0.000 claims description 5
- TVQZAMVBTVNYLA-UHFFFAOYSA-N Pranoprofen Chemical compound C1=CC=C2CC3=CC(C(C(O)=O)C)=CC=C3OC2=N1 TVQZAMVBTVNYLA-UHFFFAOYSA-N 0.000 claims description 4
- MUXFZBHBYYYLTH-UHFFFAOYSA-N Zaltoprofen Chemical compound O=C1CC2=CC(C(C(O)=O)C)=CC=C2SC2=CC=CC=C21 MUXFZBHBYYYLTH-UHFFFAOYSA-N 0.000 claims description 4
- 239000007795 chemical reaction product Substances 0.000 claims description 4
- 229960000616 diflunisal Drugs 0.000 claims description 4
- HUPFGZXOMWLGNK-UHFFFAOYSA-N diflunisal Chemical compound C1=C(O)C(C(=O)O)=CC(C=2C(=CC(F)=CC=2)F)=C1 HUPFGZXOMWLGNK-UHFFFAOYSA-N 0.000 claims description 4
- 229960003101 pranoprofen Drugs 0.000 claims description 4
- 229960002905 tolfenamic acid Drugs 0.000 claims description 4
- YEZNLOUZAIOMLT-UHFFFAOYSA-N tolfenamic acid Chemical compound CC1=C(Cl)C=CC=C1NC1=CC=CC=C1C(O)=O YEZNLOUZAIOMLT-UHFFFAOYSA-N 0.000 claims description 4
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 4
- 229950004227 zaltoprofen Drugs 0.000 claims description 4
- APQPGQGAWABJLN-UHFFFAOYSA-N Floctafenine Chemical compound OCC(O)COC(=O)C1=CC=CC=C1NC1=CC=NC2=C(C(F)(F)F)C=CC=C12 APQPGQGAWABJLN-UHFFFAOYSA-N 0.000 claims description 3
- 125000000816 ethylene group Chemical group [H]C([H])([*:1])C([H])([H])[*:2] 0.000 claims description 3
- 229960003240 floctafenine Drugs 0.000 claims description 3
- 238000010999 medical injection Methods 0.000 claims description 3
- 125000004805 propylene group Chemical group [H]C([H])([H])C([H])([*:1])C([H])([H])[*:2] 0.000 claims description 3
- 125000003258 trimethylene group Chemical group [H]C([H])([*:2])C([H])([H])C([H])([H])[*:1] 0.000 claims description 3
- 229940121363 anti-inflammatory agent Drugs 0.000 claims description 2
- 239000002260 anti-inflammatory agent Substances 0.000 claims description 2
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 claims 4
- 125000000600 disaccharide group Chemical group 0.000 claims 4
- 125000001183 hydrocarbyl group Chemical group 0.000 claims 2
- YMBXTVYHTMGZDW-UHFFFAOYSA-N loxoprofen Chemical compound C1=CC(C(C(O)=O)C)=CC=C1CC1C(=O)CCC1 YMBXTVYHTMGZDW-UHFFFAOYSA-N 0.000 claims 2
- 229960005489 paracetamol Drugs 0.000 claims 2
- 230000008569 process Effects 0.000 abstract description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 200
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 198
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 187
- 239000000126 substance Substances 0.000 description 132
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 125
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 125
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 96
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 84
- 230000015572 biosynthetic process Effects 0.000 description 79
- 238000003786 synthesis reaction Methods 0.000 description 78
- 239000000203 mixture Substances 0.000 description 77
- 230000002829 reductive effect Effects 0.000 description 73
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 64
- 238000005160 1H NMR spectroscopy Methods 0.000 description 63
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 63
- 229920002385 Sodium hyaluronate Polymers 0.000 description 60
- 125000003118 aryl group Chemical group 0.000 description 60
- 229940010747 sodium hyaluronate Drugs 0.000 description 60
- YWIVKILSMZOHHF-QJZPQSOGSA-N sodium;(2s,3s,4s,5r,6r)-6-[(2s,3r,4r,5s,6r)-3-acetamido-2-[(2s,3s,4r,5r,6r)-6-[(2r,3r,4r,5s,6r)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2- Chemical compound [Na+].CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 YWIVKILSMZOHHF-QJZPQSOGSA-N 0.000 description 60
- 238000012360 testing method Methods 0.000 description 59
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical class [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 56
- 239000002244 precipitate Substances 0.000 description 55
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 54
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 54
- 230000036407 pain Effects 0.000 description 48
- 230000000694 effects Effects 0.000 description 46
- 238000001816 cooling Methods 0.000 description 45
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 42
- 239000007864 aqueous solution Substances 0.000 description 40
- MXZROAOUCUVNHX-UHFFFAOYSA-N 2-Aminopropanol Chemical compound CCC(N)O MXZROAOUCUVNHX-UHFFFAOYSA-N 0.000 description 37
- 150000002016 disaccharides Chemical group 0.000 description 36
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 34
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 32
- 235000017557 sodium bicarbonate Nutrition 0.000 description 32
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 32
- 238000003756 stirring Methods 0.000 description 31
- 229960000991 ketoprofen Drugs 0.000 description 29
- DKYWVDODHFEZIM-UHFFFAOYSA-N ketoprofen Chemical compound OC(=O)C(C)C1=CC=CC(C(=O)C=2C=CC=CC=2)=C1 DKYWVDODHFEZIM-UHFFFAOYSA-N 0.000 description 26
- 238000005481 NMR spectroscopy Methods 0.000 description 24
- 241000700159 Rattus Species 0.000 description 24
- SQGYOTSLMSWVJD-UHFFFAOYSA-N silver(1+) nitrate Chemical compound [Ag+].[O-]N(=O)=O SQGYOTSLMSWVJD-UHFFFAOYSA-N 0.000 description 24
- NQTADLQHYWFPDB-UHFFFAOYSA-N N-Hydroxysuccinimide Chemical compound ON1C(=O)CCC1=O NQTADLQHYWFPDB-UHFFFAOYSA-N 0.000 description 23
- AMAZPKIIXVYKEX-UHFFFAOYSA-N tert-butyl 2-amino-2-hydroxybutanoate Chemical compound CCC(N)(O)C(=O)OC(C)(C)C AMAZPKIIXVYKEX-UHFFFAOYSA-N 0.000 description 23
- WCDDVEOXEIYWFB-VXORFPGASA-N (2s,3s,4r,5r,6r)-3-[(2s,3r,5s,6r)-3-acetamido-5-hydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-4,5,6-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@@H]1C[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](C(O)=O)O[C@@H](O)[C@H](O)[C@H]1O WCDDVEOXEIYWFB-VXORFPGASA-N 0.000 description 21
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 20
- 229940014041 hyaluronate Drugs 0.000 description 20
- 229910052938 sodium sulfate Inorganic materials 0.000 description 20
- 235000011152 sodium sulphate Nutrition 0.000 description 20
- 238000011282 treatment Methods 0.000 description 20
- 230000018044 dehydration Effects 0.000 description 19
- 238000006297 dehydration reaction Methods 0.000 description 19
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 18
- 238000004128 high performance liquid chromatography Methods 0.000 description 18
- 229910052739 hydrogen Inorganic materials 0.000 description 18
- 239000011780 sodium chloride Substances 0.000 description 18
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 17
- 238000001035 drying Methods 0.000 description 17
- 239000002904 solvent Substances 0.000 description 17
- 229960000549 4-dimethylaminophenol Drugs 0.000 description 16
- 239000007788 liquid Substances 0.000 description 16
- 238000010898 silica gel chromatography Methods 0.000 description 16
- 210000002683 foot Anatomy 0.000 description 15
- 239000007787 solid Substances 0.000 description 15
- 229940124597 therapeutic agent Drugs 0.000 description 14
- LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide Substances CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 description 13
- 102100038280 Prostaglandin G/H synthase 2 Human genes 0.000 description 13
- 108050003267 Prostaglandin G/H synthase 2 Proteins 0.000 description 13
- 239000008186 active pharmaceutical agent Substances 0.000 description 13
- 229960001193 diclofenac sodium Drugs 0.000 description 13
- JGMJQSFLQWGYMQ-UHFFFAOYSA-M sodium;2,6-dichloro-n-phenylaniline;acetate Chemical compound [Na+].CC([O-])=O.ClC1=CC=CC(Cl)=C1NC1=CC=CC=C1 JGMJQSFLQWGYMQ-UHFFFAOYSA-M 0.000 description 13
- 210000005222 synovial tissue Anatomy 0.000 description 13
- RNHDAKUGFHSZEV-UHFFFAOYSA-N 1,4-dioxane;hydrate Chemical compound O.C1COCCO1 RNHDAKUGFHSZEV-UHFFFAOYSA-N 0.000 description 12
- 239000002671 adjuvant Substances 0.000 description 12
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 12
- 210000000629 knee joint Anatomy 0.000 description 12
- 229910001961 silver nitrate Inorganic materials 0.000 description 12
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 11
- CMWTZPSULFXXJA-UHFFFAOYSA-N Naproxen Natural products C1=C(C(C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-UHFFFAOYSA-N 0.000 description 11
- 230000008034 disappearance Effects 0.000 description 11
- 229960002009 naproxen Drugs 0.000 description 11
- CMWTZPSULFXXJA-VIFPVBQESA-N naproxen Chemical compound C1=C([C@H](C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-VIFPVBQESA-N 0.000 description 11
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 10
- 206010002091 Anaesthesia Diseases 0.000 description 9
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 9
- 230000037005 anaesthesia Effects 0.000 description 9
- 230000002401 inhibitory effect Effects 0.000 description 9
- 238000001556 precipitation Methods 0.000 description 9
- 150000003839 salts Chemical class 0.000 description 9
- 239000003513 alkali Substances 0.000 description 8
- 239000012530 fluid Substances 0.000 description 8
- 239000011734 sodium Substances 0.000 description 8
- 230000001954 sterilising effect Effects 0.000 description 8
- 238000004659 sterilization and disinfection Methods 0.000 description 8
- 238000013268 sustained release Methods 0.000 description 8
- 239000012730 sustained-release form Substances 0.000 description 8
- 210000001179 synovial fluid Anatomy 0.000 description 8
- 210000001258 synovial membrane Anatomy 0.000 description 8
- 206010061218 Inflammation Diseases 0.000 description 7
- 210000004027 cell Anatomy 0.000 description 7
- 230000004054 inflammatory process Effects 0.000 description 7
- 239000012044 organic layer Substances 0.000 description 7
- ZNZJJSYHZBXQSM-UHFFFAOYSA-N propane-2,2-diamine Chemical compound CC(C)(N)N ZNZJJSYHZBXQSM-UHFFFAOYSA-N 0.000 description 7
- FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 description 6
- 102000004877 Insulin Human genes 0.000 description 6
- 108090001061 Insulin Proteins 0.000 description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- 230000009471 action Effects 0.000 description 6
- 239000003125 aqueous solvent Substances 0.000 description 6
- 229940125396 insulin Drugs 0.000 description 6
- 201000008482 osteoarthritis Diseases 0.000 description 6
- 125000006239 protecting group Chemical group 0.000 description 6
- 239000011541 reaction mixture Substances 0.000 description 6
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 5
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 5
- QRZAKQDHEVVFRX-UHFFFAOYSA-N biphenyl-4-ylacetic acid Chemical compound C1=CC(CC(=O)O)=CC=C1C1=CC=CC=C1 QRZAKQDHEVVFRX-UHFFFAOYSA-N 0.000 description 5
- 239000008280 blood Substances 0.000 description 5
- 210000004369 blood Anatomy 0.000 description 5
- 229910052799 carbon Inorganic materials 0.000 description 5
- 230000001079 digestive effect Effects 0.000 description 5
- 239000000428 dust Substances 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 229960000192 felbinac Drugs 0.000 description 5
- 150000002430 hydrocarbons Chemical group 0.000 description 5
- 210000003141 lower extremity Anatomy 0.000 description 5
- 238000006386 neutralization reaction Methods 0.000 description 5
- 229910052708 sodium Inorganic materials 0.000 description 5
- 159000000000 sodium salts Chemical class 0.000 description 5
- 230000001629 suppression Effects 0.000 description 5
- 230000008961 swelling Effects 0.000 description 5
- 230000002194 synthesizing effect Effects 0.000 description 5
- 238000010792 warming Methods 0.000 description 5
- UEDDHBVGNLVMRQ-UHFFFAOYSA-N 2-aminopentane-1,5-diol Chemical compound OCC(N)CCCO UEDDHBVGNLVMRQ-UHFFFAOYSA-N 0.000 description 4
- KJJPLEZQSCZCKE-UHFFFAOYSA-N 2-aminopropane-1,3-diol Chemical compound OCC(N)CO KJJPLEZQSCZCKE-UHFFFAOYSA-N 0.000 description 4
- 241000894006 Bacteria Species 0.000 description 4
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 4
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 4
- 102000004190 Enzymes Human genes 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 4
- 208000009386 Experimental Arthritis Diseases 0.000 description 4
- IAJILQKETJEXLJ-UHFFFAOYSA-N Galacturonsaeure Natural products O=CC(O)C(O)C(O)C(O)C(O)=O IAJILQKETJEXLJ-UHFFFAOYSA-N 0.000 description 4
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 4
- 229940124761 MMP inhibitor Drugs 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- 125000001309 chloro group Chemical group Cl* 0.000 description 4
- XEYBRNLFEZDVAW-ARSRFYASSA-N dinoprostone Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(O)=O XEYBRNLFEZDVAW-ARSRFYASSA-N 0.000 description 4
- 238000011156 evaluation Methods 0.000 description 4
- 238000000605 extraction Methods 0.000 description 4
- 238000001125 extrusion Methods 0.000 description 4
- 238000000338 in vitro Methods 0.000 description 4
- 210000003127 knee Anatomy 0.000 description 4
- 208000030175 lameness Diseases 0.000 description 4
- 230000004060 metabolic process Effects 0.000 description 4
- 239000011259 mixed solution Substances 0.000 description 4
- 230000003472 neutralizing effect Effects 0.000 description 4
- 206010039073 rheumatoid arthritis Diseases 0.000 description 4
- 230000002459 sustained effect Effects 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- 239000006188 syrup Substances 0.000 description 4
- 235000020357 syrup Nutrition 0.000 description 4
- 238000005406 washing Methods 0.000 description 4
- CFNLFIWRSNDUPA-UHFFFAOYSA-N 1-aminopropan-1-ol;2-(3-benzoylphenyl)propanoic acid;hydrochloride Chemical compound Cl.CCC(N)O.OC(=O)C(C)C1=CC=CC(C(=O)C=2C=CC=CC=2)=C1 CFNLFIWRSNDUPA-UHFFFAOYSA-N 0.000 description 3
- SRNGZYIXFGEUSR-UHFFFAOYSA-N 1-aminopropan-1-ol;2-[4-(2-methylpropyl)phenyl]propanoic acid;hydrochloride Chemical compound Cl.CCC(N)O.CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 SRNGZYIXFGEUSR-UHFFFAOYSA-N 0.000 description 3
- MYTQODYHTKSNJM-UHFFFAOYSA-N 2-(3-benzoylphenyl)propanoic acid;tert-butyl n-(1,3-dihydroxypropan-2-yl)carbamate Chemical compound CC(C)(C)OC(=O)NC(CO)CO.OC(=O)C(C)C1=CC=CC(C(=O)C=2C=CC=CC=2)=C1 MYTQODYHTKSNJM-UHFFFAOYSA-N 0.000 description 3
- VRPJIFMKZZEXLR-UHFFFAOYSA-N 2-[(2-methylpropan-2-yl)oxycarbonylamino]acetic acid Chemical compound CC(C)(C)OC(=O)NCC(O)=O VRPJIFMKZZEXLR-UHFFFAOYSA-N 0.000 description 3
- UPANPLZJWJNSMT-UHFFFAOYSA-N 2-acetyloxybenzoic acid;tert-butyl 2-amino-2-hydroxybutanoate Chemical compound CCC(N)(O)C(=O)OC(C)(C)C.CC(=O)OC1=CC=CC=C1C(O)=O UPANPLZJWJNSMT-UHFFFAOYSA-N 0.000 description 3
- KGTBYHGTQFWKLE-UHFFFAOYSA-N 2-aminopentane-1,5-diol;2-(3-benzoylphenyl)propanoic acid;hydrochloride Chemical compound Cl.OCC(N)CCCO.OC(=O)C(C)C1=CC=CC(C(=O)C=2C=CC=CC=2)=C1 KGTBYHGTQFWKLE-UHFFFAOYSA-N 0.000 description 3
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 3
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 3
- 208000019300 CLIPPERS Diseases 0.000 description 3
- 229940124638 COX inhibitor Drugs 0.000 description 3
- PIWKPBJCKXDKJR-UHFFFAOYSA-N Isoflurane Chemical compound FC(F)OC(Cl)C(F)(F)F PIWKPBJCKXDKJR-UHFFFAOYSA-N 0.000 description 3
- WGZOQVCBCACCDL-UHFFFAOYSA-N OC(=O)C(C)C1=CC(C(=O)C2=CC=CC=C2)=CC=C1.NC(CC)O Chemical compound OC(=O)C(C)C1=CC(C(=O)C2=CC=CC=C2)=CC=C1.NC(CC)O WGZOQVCBCACCDL-UHFFFAOYSA-N 0.000 description 3
- 206010030113 Oedema Diseases 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- AEMOLEFTQBMNLQ-WAXACMCWSA-N alpha-D-glucuronic acid Chemical compound O[C@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-WAXACMCWSA-N 0.000 description 3
- QGZKDVFQNNGYKY-UHFFFAOYSA-N ammonia Natural products N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 3
- 208000021930 chronic lymphocytic inflammation with pontine perivascular enhancement responsive to steroids Diseases 0.000 description 3
- 230000007423 decrease Effects 0.000 description 3
- 238000012377 drug delivery Methods 0.000 description 3
- 239000002158 endotoxin Substances 0.000 description 3
- 150000002148 esters Chemical class 0.000 description 3
- 239000004744 fabric Substances 0.000 description 3
- 230000006698 induction Effects 0.000 description 3
- 230000001939 inductive effect Effects 0.000 description 3
- 150000007529 inorganic bases Chemical class 0.000 description 3
- 229960002725 isoflurane Drugs 0.000 description 3
- 238000011068 loading method Methods 0.000 description 3
- BAZQYVYVKYOAGO-UHFFFAOYSA-M loxoprofen sodium hydrate Chemical compound O.O.[Na+].C1=CC(C(C([O-])=O)C)=CC=C1CC1C(=O)CCC1 BAZQYVYVKYOAGO-UHFFFAOYSA-M 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 3
- 238000007423 screening assay Methods 0.000 description 3
- 238000006467 substitution reaction Methods 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 238000011200 topical administration Methods 0.000 description 3
- VLCWPMGRZFIWFQ-UHFFFAOYSA-N 1-hydrazinylpropan-1-ol Chemical compound CCC(O)NN VLCWPMGRZFIWFQ-UHFFFAOYSA-N 0.000 description 2
- FIJZPUATIVJUII-UHFFFAOYSA-N 2-(3-benzoylphenyl)propanoic acid;tert-butyl 2-amino-2,3-dihydroxybutanoate Chemical compound CC(O)C(N)(O)C(=O)OC(C)(C)C.OC(=O)C(C)C1=CC=CC(C(=O)C=2C=CC=CC=2)=C1 FIJZPUATIVJUII-UHFFFAOYSA-N 0.000 description 2
- VBDRUWNLZWCRBL-UHFFFAOYSA-N 2-(3-benzoylphenyl)propanoic acid;tert-butyl 2-amino-2,6-dihydroxyhexanoate Chemical compound CC(C)(C)OC(=O)C(N)(O)CCCCO.OC(=O)C(C)C1=CC=CC(C(=O)C=2C=CC=CC=2)=C1 VBDRUWNLZWCRBL-UHFFFAOYSA-N 0.000 description 2
- HYHADHASZAVVNE-UHFFFAOYSA-N 2-(3-benzoylphenyl)propanoic acid;tert-butyl 2-amino-2-hydroxybutanoate Chemical compound CCC(N)(O)C(=O)OC(C)(C)C.OC(=O)C(C)C1=CC=CC(C(=O)C=2C=CC=CC=2)=C1 HYHADHASZAVVNE-UHFFFAOYSA-N 0.000 description 2
- QTURZYOOXBLGQG-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol 2-(3-benzoylphenyl)propanoic acid 2-[(2-methylpropan-2-yl)oxycarbonylamino]acetic acid Chemical compound NC(CO)(CO)CO.CC(C)(C)OC(=O)NCC(O)=O.CC(C(O)=O)c1cccc(c1)C(=O)c1ccccc1 QTURZYOOXBLGQG-UHFFFAOYSA-N 0.000 description 2
- XVENUYZHGUNEND-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol 2-(3-benzoylphenyl)propanoic acid hydrochloride Chemical compound Cl.OC(=O)C(C)C1=CC(C(=O)C2=CC=CC=C2)=CC=C1.OCC(N)(CO)CO XVENUYZHGUNEND-UHFFFAOYSA-N 0.000 description 2
- VMJBQVCCDYSMNP-UHFFFAOYSA-N 3-aminopropane-1,2-diol;2-(3-benzoylphenyl)propanoic acid;hydrochloride Chemical compound Cl.NCC(O)CO.OC(=O)C(C)C1=CC=CC(C(=O)C=2C=CC=CC=2)=C1 VMJBQVCCDYSMNP-UHFFFAOYSA-N 0.000 description 2
- 241000272875 Ardeidae Species 0.000 description 2
- 239000004471 Glycine Substances 0.000 description 2
- 229920000084 Gum arabic Polymers 0.000 description 2
- YQEZLKZALYSWHR-UHFFFAOYSA-N Ketamine Chemical compound C=1C=CC=C(Cl)C=1C1(NC)CCCCC1=O YQEZLKZALYSWHR-UHFFFAOYSA-N 0.000 description 2
- 208000003947 Knee Osteoarthritis Diseases 0.000 description 2
- ATUOYWHBWRKTHZ-UHFFFAOYSA-N Propane Chemical compound CCC ATUOYWHBWRKTHZ-UHFFFAOYSA-N 0.000 description 2
- 102000004005 Prostaglandin-endoperoxide synthases Human genes 0.000 description 2
- 108090000459 Prostaglandin-endoperoxide synthases Proteins 0.000 description 2
- 241000978776 Senegalia senegal Species 0.000 description 2
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 2
- 239000007983 Tris buffer Substances 0.000 description 2
- 239000000205 acacia gum Substances 0.000 description 2
- 235000010489 acacia gum Nutrition 0.000 description 2
- 150000008065 acid anhydrides Chemical class 0.000 description 2
- 206010003246 arthritis Diseases 0.000 description 2
- 239000002585 base Substances 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- UCMIRNVEIXFBKS-UHFFFAOYSA-N beta-alanine Chemical compound NCCC(O)=O UCMIRNVEIXFBKS-UHFFFAOYSA-N 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 239000007853 buffer solution Substances 0.000 description 2
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 238000009833 condensation Methods 0.000 description 2
- 230000005494 condensation Effects 0.000 description 2
- 238000006731 degradation reaction Methods 0.000 description 2
- 238000005238 degreasing Methods 0.000 description 2
- BTFSVBAFIHSVBO-UHFFFAOYSA-N dichloromethane;1,4-dioxane Chemical compound ClCCl.C1COCCO1 BTFSVBAFIHSVBO-UHFFFAOYSA-N 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- MVEAAGBEUOMFRX-UHFFFAOYSA-N ethyl acetate;hydrochloride Chemical compound Cl.CCOC(C)=O MVEAAGBEUOMFRX-UHFFFAOYSA-N 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 description 2
- 238000002695 general anesthesia Methods 0.000 description 2
- 239000003193 general anesthetic agent Substances 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 230000002209 hydrophobic effect Effects 0.000 description 2
- NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 2
- 239000002955 immunomodulating agent Substances 0.000 description 2
- 230000001976 improved effect Effects 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 229960003299 ketamine Drugs 0.000 description 2
- 239000010410 layer Substances 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 229910052709 silver Inorganic materials 0.000 description 2
- 239000004332 silver Substances 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L sodium carbonate Substances [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- 238000002798 spectrophotometry method Methods 0.000 description 2
- 239000007921 spray Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- BLDQEEPGDVRCQC-UHFFFAOYSA-N tert-butyl 2-amino-3-bromopropanoate Chemical compound CC(C)(C)OC(=O)C(N)CBr BLDQEEPGDVRCQC-UHFFFAOYSA-N 0.000 description 2
- JQZFTTNXRQSVDT-UHFFFAOYSA-N tert-butyl 2-amino-4-bromobutanoate Chemical compound CC(C)(C)OC(=O)C(N)CCBr JQZFTTNXRQSVDT-UHFFFAOYSA-N 0.000 description 2
- JHBKBRLRYPYBLP-UHFFFAOYSA-N tert-butyl n-(1,3-dihydroxypropan-2-yl)carbamate Chemical compound CC(C)(C)OC(=O)NC(CO)CO JHBKBRLRYPYBLP-UHFFFAOYSA-N 0.000 description 2
- PYFXOUCQTPUBOG-UHFFFAOYSA-N tert-butyl n-[1,3-dihydroxy-2-(hydroxymethyl)propan-2-yl]carbamate Chemical compound CC(C)(C)OC(=O)NC(CO)(CO)CO PYFXOUCQTPUBOG-UHFFFAOYSA-N 0.000 description 2
- 125000003396 thiol group Chemical group [H]S* 0.000 description 2
- OGNSCSPNOLGXSM-UHFFFAOYSA-N (+/-)-DABA Natural products NCCC(N)C(O)=O OGNSCSPNOLGXSM-UHFFFAOYSA-N 0.000 description 1
- RDJGLLICXDHJDY-NSHDSACASA-N (2s)-2-(3-phenoxyphenyl)propanoic acid Chemical compound OC(=O)[C@@H](C)C1=CC=CC(OC=2C=CC=CC=2)=C1 RDJGLLICXDHJDY-NSHDSACASA-N 0.000 description 1
- VUAFHZCUKUDDBC-SCSAIBSYSA-N (2s)-2-[(2-methyl-2-sulfanylpropanoyl)amino]-3-sulfanylpropanoic acid Chemical compound CC(C)(S)C(=O)N[C@H](CS)C(O)=O VUAFHZCUKUDDBC-SCSAIBSYSA-N 0.000 description 1
- NAWXUBYGYWOOIX-SFHVURJKSA-N (2s)-2-[[4-[2-(2,4-diaminoquinazolin-6-yl)ethyl]benzoyl]amino]-4-methylidenepentanedioic acid Chemical compound C1=CC2=NC(N)=NC(N)=C2C=C1CCC1=CC=C(C(=O)N[C@@H](CC(=C)C(O)=O)C(O)=O)C=C1 NAWXUBYGYWOOIX-SFHVURJKSA-N 0.000 description 1
- ASOKPJOREAFHNY-UHFFFAOYSA-N 1-Hydroxybenzotriazole Chemical compound C1=CC=C2N(O)N=NC2=C1 ASOKPJOREAFHNY-UHFFFAOYSA-N 0.000 description 1
- UAORBQCNBFOUQC-UHFFFAOYSA-N 1-aminopropan-1-ol;2-(4-phenylphenyl)acetic acid;hydrochloride Chemical compound Cl.CCC(N)O.C1=CC(CC(=O)O)=CC=C1C1=CC=CC=C1 UAORBQCNBFOUQC-UHFFFAOYSA-N 0.000 description 1
- PCAXITAPTVOLGL-UHFFFAOYSA-N 2,3-diaminophenol Chemical compound NC1=CC=CC(O)=C1N PCAXITAPTVOLGL-UHFFFAOYSA-N 0.000 description 1
- XZGMITWLRIKISV-UHFFFAOYSA-N 2-acetyloxybenzoic acid;1-aminopropan-1-ol;hydrochloride Chemical compound Cl.CCC(N)O.CC(=O)OC1=CC=CC=C1C(O)=O XZGMITWLRIKISV-UHFFFAOYSA-N 0.000 description 1
- QNNKEMLHZGNEGI-UHFFFAOYSA-N 2-aminoacetic acid 2-amino-2-(hydroxymethyl)propane-1,3-diol 2-(3-benzoylphenyl)propanoic acid hydrochloride Chemical compound Cl.NCC(O)=O.NC(CO)(CO)CO.CC(C(O)=O)c1cccc(c1)C(=O)c1ccccc1 QNNKEMLHZGNEGI-UHFFFAOYSA-N 0.000 description 1
- MIDXCONKKJTLDX-UHFFFAOYSA-N 3,5-dimethylcyclopentane-1,2-dione Chemical compound CC1CC(C)C(=O)C1=O MIDXCONKKJTLDX-UHFFFAOYSA-N 0.000 description 1
- KQIGMPWTAHJUMN-UHFFFAOYSA-N 3-aminopropane-1,2-diol Chemical compound NCC(O)CO KQIGMPWTAHJUMN-UHFFFAOYSA-N 0.000 description 1
- PQIYSSSTRHVOBW-UHFFFAOYSA-N 3-bromopropan-1-amine;hydron;bromide Chemical compound Br.NCCCBr PQIYSSSTRHVOBW-UHFFFAOYSA-N 0.000 description 1
- HACQKMWYOKGLET-UHFFFAOYSA-N 4-amino-4-(3-hydroxypropyl)heptane-1,7-diol Chemical compound OCCCC(N)(CCCO)CCCO HACQKMWYOKGLET-UHFFFAOYSA-N 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 239000004215 Carbon black (E152) Substances 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 108010067770 Endopeptidase K Proteins 0.000 description 1
- 206010015719 Exsanguination Diseases 0.000 description 1
- 101000608720 Helianthus annuus 10 kDa late embryogenesis abundant protein Proteins 0.000 description 1
- OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical compound NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 description 1
- 206010023126 Jaundice Diseases 0.000 description 1
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 241000186359 Mycobacterium Species 0.000 description 1
- 238000011887 Necropsy Methods 0.000 description 1
- 206010030124 Oedema peripheral Diseases 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 229940124158 Protease/peptidase inhibitor Drugs 0.000 description 1
- 101500026339 Rattus norvegicus Bradykinin Proteins 0.000 description 1
- 208000025747 Rheumatic disease Diseases 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- FKNQFGJONOIPTF-UHFFFAOYSA-N Sodium cation Chemical compound [Na+] FKNQFGJONOIPTF-UHFFFAOYSA-N 0.000 description 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- YZCKVEUIGOORGS-NJFSPNSNSA-N Tritium Chemical compound [3H] YZCKVEUIGOORGS-NJFSPNSNSA-N 0.000 description 1
- 238000011481 absorbance measurement Methods 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 229960004892 acemetacin Drugs 0.000 description 1
- FSQKKOOTNAMONP-UHFFFAOYSA-N acemetacin Chemical compound CC1=C(CC(=O)OCC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 FSQKKOOTNAMONP-UHFFFAOYSA-N 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- IAJILQKETJEXLJ-QTBDOELSSA-N aldehydo-D-glucuronic acid Chemical compound O=C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)C(O)=O IAJILQKETJEXLJ-QTBDOELSSA-N 0.000 description 1
- 229910001413 alkali metal ion Inorganic materials 0.000 description 1
- 229910001420 alkaline earth metal ion Inorganic materials 0.000 description 1
- 125000004103 aminoalkyl group Chemical group 0.000 description 1
- 239000012062 aqueous buffer Substances 0.000 description 1
- 239000012752 auxiliary agent Substances 0.000 description 1
- 229940000635 beta-alanine Drugs 0.000 description 1
- 238000006065 biodegradation reaction Methods 0.000 description 1
- 229960004272 bucillamine Drugs 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 159000000007 calcium salts Chemical class 0.000 description 1
- 235000013736 caramel Nutrition 0.000 description 1
- 150000001721 carbon Chemical group 0.000 description 1
- 210000000845 cartilage Anatomy 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 238000004737 colorimetric analysis Methods 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 238000010908 decantation Methods 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 238000010511 deprotection reaction Methods 0.000 description 1
- 150000004985 diamines Chemical class 0.000 description 1
- MQYQOVYIJOLTNX-UHFFFAOYSA-N dichloromethane;n,n-dimethylformamide Chemical compound ClCCl.CN(C)C=O MQYQOVYIJOLTNX-UHFFFAOYSA-N 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 210000002249 digestive system Anatomy 0.000 description 1
- ACHABJPIRMAIRY-UHFFFAOYSA-N dimethylphosphane;hydrochloride Chemical compound [Cl-].C[PH2+]C ACHABJPIRMAIRY-UHFFFAOYSA-N 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 229920001971 elastomer Polymers 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 238000001976 enzyme digestion Methods 0.000 description 1
- 238000012869 ethanol precipitation Methods 0.000 description 1
- 210000003414 extremity Anatomy 0.000 description 1
- 230000002550 fecal effect Effects 0.000 description 1
- 229960001419 fenoprofen Drugs 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 125000001153 fluoro group Chemical group F* 0.000 description 1
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 description 1
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 1
- 230000005021 gait Effects 0.000 description 1
- 229960003692 gamma aminobutyric acid Drugs 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 238000012812 general test Methods 0.000 description 1
- 229940097043 glucuronic acid Drugs 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 229960002449 glycine Drugs 0.000 description 1
- 229910052736 halogen Inorganic materials 0.000 description 1
- 150000002367 halogens Chemical class 0.000 description 1
- 210000000548 hind-foot Anatomy 0.000 description 1
- 210000004394 hip joint Anatomy 0.000 description 1
- KIUKXJAPPMFGSW-MNSSHETKSA-N hyaluronan Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)C1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H](C(O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-MNSSHETKSA-N 0.000 description 1
- 229940099552 hyaluronan Drugs 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 description 1
- 208000026278 immune system disease Diseases 0.000 description 1
- 229940121354 immunomodulator Drugs 0.000 description 1
- 229960003444 immunosuppressant agent Drugs 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 239000002198 insoluble material Substances 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 210000002414 leg Anatomy 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 159000000003 magnesium salts Chemical class 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 238000005360 mashing Methods 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 229940126601 medicinal product Drugs 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 229910021645 metal ion Inorganic materials 0.000 description 1
- 229960000485 methotrexate Drugs 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 239000012434 nucleophilic reagent Substances 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 210000004417 patella Anatomy 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
- 102000013415 peroxidase activity proteins Human genes 0.000 description 1
- 108040007629 peroxidase activity proteins Proteins 0.000 description 1
- 125000000612 phthaloyl group Chemical group C(C=1C(C(=O)*)=CC=CC1)(=O)* 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 239000001294 propane Substances 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- WGYKZJWCGVVSQN-UHFFFAOYSA-N propylamine Chemical compound CCCN WGYKZJWCGVVSQN-UHFFFAOYSA-N 0.000 description 1
- 150000003180 prostaglandins Chemical class 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 230000000552 rheumatic effect Effects 0.000 description 1
- 239000005060 rubber Substances 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 150000003354 serine derivatives Chemical class 0.000 description 1
- 210000000323 shoulder joint Anatomy 0.000 description 1
- 238000007086 side reaction Methods 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 229910001415 sodium ion Inorganic materials 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- OAPDLBHLMVYMCW-UHFFFAOYSA-M sodium;2-(3-benzoylphenyl)propanoate Chemical compound [Na+].[O-]C(=O)C(C)C1=CC=CC(C(=O)C=2C=CC=CC=2)=C1 OAPDLBHLMVYMCW-UHFFFAOYSA-M 0.000 description 1
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical class O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 1
- 238000005063 solubilization Methods 0.000 description 1
- 230000007928 solubilization Effects 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- ACTRVOBWPAIOHC-XIXRPRMCSA-N succimer Chemical compound OC(=O)[C@@H](S)[C@@H](S)C(O)=O ACTRVOBWPAIOHC-XIXRPRMCSA-N 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 238000001308 synthesis method Methods 0.000 description 1
- 229920003051 synthetic elastomer Polymers 0.000 description 1
- 239000005061 synthetic rubber Substances 0.000 description 1
- 231100000057 systemic toxicity Toxicity 0.000 description 1
- 210000001738 temporomandibular joint Anatomy 0.000 description 1
- CQGKRQFQLAWTEF-UHFFFAOYSA-N tert-butyl 2-amino-2,3-dihydroxybutanoate Chemical compound CC(O)C(N)(O)C(=O)OC(C)(C)C CQGKRQFQLAWTEF-UHFFFAOYSA-N 0.000 description 1
- WTUAUVLMYFPEBU-UHFFFAOYSA-N tert-butyl 2-amino-2,6-dihydroxyhexanoate Chemical compound CC(C)(C)OC(=O)C(N)(O)CCCCO WTUAUVLMYFPEBU-UHFFFAOYSA-N 0.000 description 1
- YNBZQCOWGDMCIQ-UHFFFAOYSA-N tert-butyl n-amino-n-[1,3-dihydroxy-2-(hydroxymethyl)propan-2-yl]carbamate Chemical compound CC(C)(C)OC(=O)N(N)C(CO)(CO)CO YNBZQCOWGDMCIQ-UHFFFAOYSA-N 0.000 description 1
- 125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 150000003587 threonine derivatives Chemical class 0.000 description 1
- 230000036962 time dependent Effects 0.000 description 1
- PFENFDGYVLAFBR-UHFFFAOYSA-N tinoridine Chemical group C1CC=2C(C(=O)OCC)=C(N)SC=2CN1CC1=CC=CC=C1 PFENFDGYVLAFBR-UHFFFAOYSA-N 0.000 description 1
- 229950010298 tinoridine Drugs 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- 238000003260 vortexing Methods 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/60—Salicylic acid; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
- A61K31/728—Hyaluronic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
- C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
- C08B37/006—Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence; Gellans; Succinoglycans; Arabinogalactans; Tragacanth or gum tragacanth or traganth from Astragalus; Gum Karaya from Sterculia urens; Gum Ghatti from Anogeissus latifolia; Derivatives thereof
- C08B37/0063—Glycosaminoglycans or mucopolysaccharides, e.g. keratan sulfate; Derivatives thereof, e.g. fucoidan
- C08B37/0072—Hyaluronic acid, i.e. HA or hyaluronan; Derivatives thereof, e.g. crosslinked hyaluronic acid (hylan) or hyaluronates
Definitions
- the present invention relates to a hyaluronic acid derivative into which a non-steroidal anti-inflammatory compound or a disease-modifying anti-rheumatic compound is introduced via a spacer that can be degraded in vivo, and a method for producing the same.
- Sodium hyaluronate solution is used as a therapeutic agent for arthropathy such as osteoarthritis of the knee (OA) and rheumatoid arthritis of the knee (RA).
- the sodium hyaluronate solution is usually used as an injection and is directly administered to the affected joints such as knees and shoulders, and is widely used for the purpose of improving dysfunction due to arthropathy and suppressing pain.
- Non-steroidal anti-inflammatory agents are used as agents for suppressing and relieving pain due to such arthrosis.
- NSAIDs NSAIDs
- DMARDs disease-modifying anti-rheumatic compounds
- these NSAIDs are often administered orally.
- oral administration of NSAIDs is in combination with infusion of the above sodium hyaluronate solution injection.
- the problem with the use of these NSAIDs by oral administration is that the NSAIDs are absorbed, circulate in the blood, and most of them are lost before reaching the affected area. Therefore, it is necessary to take a large amount of NSAIDs to maintain an effective amount in the blood and to reach the affected area.
- Such a large amount of oral NSAIDs for oral ⁇ has a serious side effect of digestive disorders and is a problem.
- DMARDs examples include immunotherapeutic agents (immunomodulators and immunosuppressants) related to the control of immune disorders and the like, which are considered to be the cause of inflammation.
- hyaluronic acid is a polysaccharide composed of a repeating structure having a disaccharide unit of ⁇ -acetyl-D-darcosamine and D-glucuronic acid as a basic skeleton. It is known that it has a very high hydrophilicity because it has a hydroxyl group! As an example, hyaluronic acid is highly hydrophilic, that is, highly hydrated with water molecules. Hyaluronic acid can hold about 1000 times its own weight of water.
- NSAIDs drugs introduced into hyaluronic acid include, for example, a matrix protease inhibitor (MMP inhibitor), which is a therapeutic agent for arthropathy, and hyaluronic acid without a spacer or with a spacer.
- MMP inhibitor matrix protease inhibitor
- Patent Document 1 There is a report of a conjugate bonded via a compound.
- the report states that the preferred binding mode between the MMP inhibitor and hyaluronic acid is a stronger and covalent bond, and the conjugate does not dissociate or decompose into the MMP inhibitor and hyaluronic acid at the administration site.
- Patent Document 1 WO99 / 59603
- Patent Document 2 Japanese Translation of International Patent Application No. Hei 3—502704
- Patent Document 3 JP-A-9-188705
- a method of avoiding the problem of obstruction caused by oral administration of NSAIDs by injecting NSAIDs directly into the affected area is a theoretically conceivable force.
- NSAIDs are directly injected into the knee joint cavity, Due to the fast absorption, the duration of the effect of NSAIDs is short No method has been adopted.
- NSAIDs themselves aim to relieve and control pain such a method cannot be a fundamental treatment for arthropathy.
- the present invention provides a novel derivative in which NSAIDs and DMARD are chemically introduced into sodium hyaluronate, which is a therapeutic agent for arthropathy, and injects it into the affected area to alleviate, suppress, and reduce the pain associated with arthropathy.
- the aim is to provide drugs that can greatly contribute to the fundamental treatment of arthropathy, and drugs that have a sustained effect by controlling the release of NSAIDs and DMARDs.
- the present inventors have found that they can be used as injections that can be injected into the affected area of arthropathy patients, and that they can be used not only for the fundamental treatment of arthropathy but also for alleviation and suppression of pain and inflammation.
- Derivatives in which DMARD has been introduced into hyaluronic acid are suitable for the above purpose, and more preferably, in the production process, alkali treatment is performed to improve solubility and can be injected as an injectable (injectable)
- alkali treatment is performed to improve solubility and can be injected as an injectable (injectable)
- the present inventors have found that a soluble NSAIDs-introduced hyaluronic acid derivative or a soluble DMARD-introduced hyaluronic acid derivative that can be used as a solution can be obtained, and the present invention has been completed.
- the present invention is as follows.
- the anti-inflammatory compound is salicylic acid, aspirin, mefenamic acid, tolfenamic acid, flufenamic acid, diclofenac, sulindac, fenbufen, indomethacin, acemethasin, anfenfenac, etodolac, fuerbinac, ibuprofen, flurbiprofen, ketoprofen , Naproxen, pranoprofen, phenoprofen, thiaprofenic acid, oxaprozin, loxoprofen, aluminoprofen, zaltoprofen, piroxicam, tenoxicam, lornoxicam, meloxicam, tiaramid, tolmetin, diflunisal, acetamominophene, floctafentin, and thinolidine.
- the derivative according to the above (3) which is a residue of the compound selected from the group
- the spacer is a diaminoalkane having 2 to 18 carbon atoms, an aminoamino alcohol having 2 to 12 carbon atoms which may have a substituent, and an amino acid having the above-mentioned (1).
- the hyaluronic acid derivative according to any one of (1) to (5).
- a non-steroidal anti-inflammatory compound is bound to hyaluronic acid by a covalent bond, and is a derivative of hyaluronic acid, into which the anti-inflammatory compound is introduced.
- Hyaluronic acid derivative represented by the following formula (1):
- Y—CO— represents one residue of the constituent disaccharide unit of hyaluronic acid
- R 2 represents a nonsteroidal anti-inflammatory compound residue represented by Z—CO— or a hydrogen atom (however, all are hydrogen atoms) HN—R 1 — (O—) n is an HN—R 1 — (OH) n having n hydroxyl groups
- R 1 represents a linear or branched hydrocarbon group having 2 to 12 carbon atoms which may have a substituent; CO—NH— Indicates an amide bond between the carboxyl group of dacuronic acid, a constituent sugar of hyaluronic acid, and the amino group of the spacer compound, and O—CO— indicates the hydroxyl group of the spacer compound and a nonsteroidal anti-inflammatory compound. Shows an ester bond with the carboxyl group of the residue
- n represents an integer of 1 to 3.
- non-steroidal anti-steroids in the hyaluronic acid derivative The introduction rate of the inflammatory compound is 5 to 50 mol% per repeating disaccharide unit of the hyaluronic acid, and the carboxyl group in the hyaluronic acid residue constituting the hyaluronic acid derivative is a non-steroidal anti-inflammatory compound residue. Depending on the rate of introduction, it is assumed that the compound exists as an amide bond involved in binding to the spacer-bound anti-inflammatory compound residue or as a free carboxyl group not involved.
- R 3 represents a substituent or a hydrogen atom selected from a lower alkyl group and a lower alkoxyl group.
- R 4 , R 5 and R 6 each independently represent a lower alkyl group, a lower alkoxyl group or a hydroxyl group, a substituent, a halogen atom or a hydrogen atom.
- X is independently the same or different, and represents a lower alkyl group and a trifluoromethyl group.
- a substituent or a halogen atom is selected, and at least one of X is a halogen atom.
- Nonsteroidal anti-inflammatory compound power The above-mentioned (10), which is diclofunac or a derivative thereof
- R 1 in the above formula (1) is an optionally substituted ethylene group, trimethylene group or propylene group.
- Hyaluronic acid derivatives
- a solution obtained by dissolving the above-described hyaluronic acid derivative at 1.0% by weight in an aqueous medium is mixed with a porous filter (pore size (pore size) 0.22) under a temperature condition of 24 ° C. and a pressure of 5.0 kg Zcm 2. ⁇ m, 25 mm in diameter) per minute for 2 mL or more, wherein the hyaluronic acid derivative according to any one of (1) to (13) above.
- aqueous medium is an aqueous medium selected from phosphate buffered saline, physiological saline and water for injection.
- a drug comprising the hyaluronic acid derivative according to any one of (1) to (15) above as an active ingredient.
- An injection device comprising the hyaluronic acid derivative according to any one of (1) to (15) above as an active ingredient, and comprising a solution caramel having the hyaluronic acid derivative dissolved in an aqueous medium.
- a drug that can be extruded comprising the hyaluronic acid derivative according to any one of (1) to (15) above as an active ingredient, and comprising a solution caramel having the hyaluronic acid derivative dissolved in an aqueous medium.
- a syringe prepared by dissolving the hyaluronic acid derivative according to any one of (1) to (15) above in a pharmaceutically acceptable phosphate buffered saline, physiological saline, or water for injection.
- a pharmaceutically acceptable phosphate buffered saline, physiological saline, or water for injection To A medical injection kit filled and slidably sealed with a plunger for drug extrusion.
- a spacer having a site that can be degraded in a living body [0041]
- the above-mentioned (28) which is a residue of a compound capable of binding two or more anti-inflammatory compounds to one molecule of the spacer.
- the derivative according to (29) is a residue of a compound capable of binding two or more anti-inflammatory compounds to one molecule of the spacer.
- the anti-inflammatory compound is selected from the group consisting of salicylic acid, aspirin, mefenamic acid, tolfenamic acid, flufenamic acid, diclofenac, sulindac, fenbufen, indomethacin, acemethasin, anfenfenac, etodolac, fuerbinac, ibuprofen, flurbiprofen, ketoprofen , Naproxen, pranoprofen, phenoprofen, thiaprofenic acid, oxaprozin, loxoprofen, aluminoprofen, zaltoprofen, piroxicam, tenoxicam, lornoxicam, meloxicam, tiaramid, tolmetin, diflunisal, acetamominophene, floctafentin, and thinolidine.
- R 2 represents a non-steroidal anti-inflammatory compound residue represented by Z—CO— or a hydrogen atom (except when all are hydrogen atoms), and HN—R 1 — (O—) n is n Hydroxyl groups
- n is an integer of 1 to 3
- a hyaluronic acid derivative in which an anti-inflammatory compound is covalently bonded to hyaluronic acid via a spacer having a site capable of being degraded in a living body, in particular, a non-steroidal anti-inflammatory compound is covalently bonded.
- a non-steroidal anti-inflammatory compound-introduced hyaluronic acid derivative (hereinafter also referred to as substance 1 of the present invention) bound thereto, and a disease-modifying anti-rheumatic compound similarly bound by a covalent bond.
- substance 1 of the present invention bound thereto, and a disease-modifying anti-rheumatic compound similarly bound by a covalent bond.
- substance 2 of the present invention Introduced hyaluronic acid derivative (hereinafter, also referred to as substance 2 of the present invention.
- the above-mentioned substance 1 of the present invention and substance 2 of the present invention are also referred to as the substance of the present invention), and drugs containing these derivatives as active ingredients (Her
- the substance of the present invention dissolves well in buffers, physiological saline, water for injection and the like used as solvents for injections and the like, and thus can be used as injections that can be directly administered to affected areas.
- the drug of the present invention can be used for treating arthropathy, suppressing inflammation and controlling pain, and can be administered parenterally or locally (for example, intra-articular administration) as an injection.
- FIG. 1 is a view showing a pain score for a rat bradykinin-induced pain model.
- FIG. 2 is a view showing a pain score for a rat 1% silver nitrate solution-induced pain model.
- FIG. 3 is a view showing a load rate (%) of a rat 1% silver nitrate solution-induced pain model.
- FIG. 4 Introduction of aminopropanol-ketoprofen into the heron knee joint. Administration of sodium hyaluronate (KP-HA), a mixture of ketoprofen and HA, and ketoprofen. It is a figure which shows the time-dependent survival rate in a node.
- KP-HA sodium hyaluronate
- FIG. 5 is a view showing the effect of sodium hyaluronate introduced with diaminophenol diclofenac having a different induction ratio (DS) on a rat 1% silver nitrate-induced pain model in rats.
- DS induction ratio
- FIG. 6 is a graph showing the effect of oral administration of diclofunac sodium on a 1% silver nitrate-induced pain model in rats.
- FIG. 7 is a graph showing the effects of diclofenac alone and hyaluronic acid on a rat 1% silver nitrate-induced pain model.
- FIG. 8 Effect of sodium hyaluronate (65 kDa) introduced with aminoaminopropanol diclofenac, sodium hyaluronate introduced with diaminopropane diclofenac and sodium hyaluronate introduced with aminoethanol diclofenac on a 1% silver nitrate-induced pain model in rats It is a figure which shows a comparison.
- FIG. 9 (a) is a graph showing the effects (in vitro) of diclofenac sodium alone and a diclofenac-introduced hyaluronic acid derivative on COX-2.
- FIG. 9 (b) shows the effects of sodium hyaluronate alone and diclofenac-introduced hyaluronic acid derivative on COX-2 (in vitro).
- FIG. 10 (a) shows the effect of administration of a diclofenac-introduced hyaluronic acid derivative on an adjuvant-administered paw in a rat adjuvant arthritis (AIA) model.
- FIG. 10 (b) is a graph showing the effect of administration of a diclofenac-introduced hyaluronic acid derivative on an adjuvant-untreated leg in a rat adjuvant arthritis (AIA) model.
- the substance of the present invention is a hyaluronic acid derivative in which an anti-inflammatory compound is covalently bonded to hyaluronic acid via a spacer having a site that can be degraded in vivo.
- the anti-inflammatory compound is selected from non-steroidal anti-inflammatory compounds (NSAIDs or NSAIDs) and disease-modifying anti-rheumatic compounds (DMARD).
- ⁇ NSAIDs '' is used to collectively refer to non-steroidal anti-inflammatory compounds in which a plurality of compounds are classified, and ⁇ NSAID '' may refer to each non-steroidal anti-inflammatory compound. Then use it strictly, and divide it.
- the substance 1 of the present invention is a hyaluronic acid derivative in which a nonsteroidal anti-inflammatory compound is bound by a covalent bond, and has a conceptual structure represented by the following general formula (4).
- HA indicates a hyaluronic acid chain
- SP indicates a spacer residue
- NSAID indicates a nonsteroidal anti-inflammatory compound residue
- the substance 2 of the present invention is a hyaluronic acid derivative to which a disease-modifying antirheumatic compound is bound by a covalent bond, and has a conceptual structure represented by the following general formula (5).
- HA indicates a hyaluronic acid chain
- SP indicates a spacer residue
- DMARD indicates a disease-modifying antirheumatic compound residue
- aqueous solvent refers to water, a buffer solution containing water, a pharmaceutically acceptable metal salt.
- aqueous solutions and buffers containing pH adjusters and the like and specific examples include water for injection, phosphate buffered saline, and physiological saline.
- the hyaluronic acid used in the substance of the present invention has a basic skeleton consisting of a disaccharide unit formed by bonding N-acetyl-D-darcosamine and D-glucuronic acid through a j8 1,3 bond.
- This is not particularly limited as long as it is a glycosaminodalican constituted by repeating j8 1,4 bonds, that is, a commonly used hyaluronic acid.
- those obtained from any of animal origin, microbial origin, and daniological synthesis can be used.
- the weight-average molecular weight of hyaluronic acid is not particularly limited, and is, for example, 10,000 to 5,000,000. It is preferably 500,000-3,000,000, more preferably 600,000-1,500,000 and 1,500,000-3,000,000 which are the standards used as therapeutic agents for arthrosis.
- the hyaluronic acid used in the present invention forms a salt, which may be in a free state or in a pharmaceutically acceptable salt state.
- the pharmaceutically acceptable salts of hyaluronic acid include, for example, salts with alkali metal ions such as sodium salt and potassium salt, and salts with alkaline earth metal ions such as magnesium salt and calcium salt. Is mentioned.
- the hyaluronate used is particularly preferably a salt with a sodium ion, even though a salt with a pharmaceutically acceptable metal ion is preferred because of its high affinity.
- NSAIDs which are one of the anti-inflammatory compounds in the present invention, generally refer to all compounds called non-steroidal anti-inflammatory agents, and are not particularly limited. desirable. Conventionally, NSAIDs have been classified based on differences in skeleton in chemical structure.
- NSAIDs applied to the present invention for each classification include salicylic acid NSAIDs such as salicylic acid and aspirin, phenamic acid NSAIDs such as mefenamic acid, tolfenamic acid, and flufenamic acid; Sulindac, fenbufen, indomethacin, acemetacin, amphuenac, etodolac, felbinac, etc.
- Propionic acid NSAIDs such as ibuprofen, flurbiprofen, ketoprofen, naproxen, planoprofen, fenoprofen, thiap oral fenfenate, oxaprozin, loxoprofen, aluminophene Piroxicam, tenoxicam, lornoxicam, meloxicam, etc. as oxicam NSAIDs, and tiaramid, tolmetin, dimethy Le - monkeys, Asetaminofu
- NSAIDs applied to the present invention those having a functional group such as a carboxyl group, a hydroxyl group, or an amino group in the chemical structure thereof are desirable.
- the substance 1 of the present invention is not particularly limited because it is possible to select a functional group of a spacer according to the functional group of these NSAIDs, but it is not particularly limited. NSAIDs are particularly preferably used.
- a compound having a skeleton represented by the following formula (6) is more preferably used.
- R 3 represents a substituent or a hydrogen atom selected from a lower alkyl group and a lower alkoxyl group.
- R 4 , R 5 and R 6 each independently represent a lower alkyl group, a lower alkoxyl group or a hydroxyl group, a substituent, a halogen atom or a hydrogen atom.
- X is independently the same or different, and represents a lower alkyl group and a trifluoromethyl group.
- a substituent or a halogen atom is selected, and at least one of X is a halogen atom.
- the lower alkyl group and the lower alkoxyl group may have a branch, and the lower alkyl group and the lower alkoxyl group having a carbon number of 11 to 12 may preferably have a branched carbon atom. Even more preferred are lower alkyl groups and lower alkoxyl groups.
- R 3 is located at the 5-position when the carboxymethyl group is at the 1-position and the amino residue is at the 2-position at the benzene ring to which R 3 is bonded. Preferably they are linked.
- the compound represented by the above formula (2) for example, the compound described in WO99Z11605 can be mentioned, and the content of the publication is incorporated by reference in the present specification.
- the carboxyl group of the NSAID may be in a free form or may form a salt.
- DMARD which is another anti-inflammatory compound in the present invention, generally refers to drugs generally used as anti-rheumatic drugs, and is not particularly limited. However, in its chemical structure, carboxyl group, hydroxyl group, Those having a functional group such as an amino group and a mercapto group are desirable. Examples of DMARDs include aktarit, methotrexate, salazosulfaviridine, and bucillamine. [0063] As the anti-inflammatory compound in the present invention, a compound having a carboxyl group among the above-mentioned NSAIDs and DMARDs is preferable.
- the substance of the present invention does not necessarily need to have one kind of NSAID or DMARD introduced, and also includes a hyaluronic acid derivative into which two or more kinds of NSAIS or DMARD are introduced.
- the spacer represented by the SP is a spacer having a site that can be degraded in a living body, and has a functional group that binds to hyaluronic acid and a function that binds to NSAIDs or DMARD.
- Compounds each having at least one group hereinafter, also referred to as spacer compounds 5)
- the site of the spacer that can be degraded in the living body is not particularly limited as long as the NSAIDs or DMARDs released from the hyaluronic acid derivative have an effect, but the NSAIDs or DMARD and the spacer are not limited. Desirable to be decomposed at the binding site of! / ,.
- the functional group of the spacer compound can be variously selected depending on the mode of binding to hyaluronic acid and NSAIDs or DMARD, respectively. For example, when introducing a spacer with a carboxyl group of hyaluronic acid and an amide bond, a spacer compound having an amino group is selected.When introducing a spacer with a carboxyl group of hyaluronic acid and an ester bond, a hydroxyl group is used. When a spacer compound is selected and introduced via a hydroxyl group of hyaluronic acid and an ester bond, a spacer compound having a carboxyl group can be selected.
- a spacer compound having an amino group that can be introduced into the carboxyl group of hyaluronic acid through an amide bond is mentioned as one of the preferable forms because of its ease of introduction into hyaluronic acid and stability in vivo. .
- the functional group of the spacer compound that binds to NSAIDs or DMARD can be selected according to the functional group of NSAIDs or DMARD.
- NSAIDs or DMARDs having a hydroxyl group if a spacer compound having a carboxyl group is selected, they can be bonded by an ester bond, and in the case of NSAIDs or DMARDs having a carboxyl group, they have a hydroxyl group.
- a spacer compound it can be linked by an ester bond.
- a spacer compound having an amino group is selected, it can be bonded by an amide bond.
- a thioester bond can be selected by selecting one spacer compound having a carboxyl group. Can be combined.
- a spacer compound having a functional group capable of binding to NSAIDs or DMARD by an ester bond in consideration of the ease of decomposition in a living body is desirable, and the carboxyl group of NSAIDs or DMARD is more desirable. It is particularly preferred that the hydroxyl group of the spacer compound is bonded to the hydroxyl group of the spacer compound by an ester bond.
- the spacer compound can be appropriately selected according to the characteristics of hyaluronic acid, NSAIDs, or DMARD.
- diaminoalkane having 2 to 18 carbon atoms, 2 carbon atoms which may have a substituent, — 12 aminoalkyl alcohols, amino acids and the like.
- the amino acid may be a natural or unnatural amino acid, and is not particularly limited, and preferably includes glycine, ⁇ -alanine, and ⁇ -aminobutyric acid.
- a spacer compound is desirably an example of a substituted or unsubstituted aminoalkyl having 2 to 12 carbon atoms. Alcohol.
- spacer compound having two or more of these functional groups binding to NSAIDs or DMARDs in one molecule hereinafter, also referred to as a polyvalent spacer compound may be used.
- a multivalent spacer compound When a multivalent spacer compound is selected, it is possible to simultaneously bind a plurality of NSAIDs or DMARDs to one spacer. Therefore, it becomes possible to simultaneously introduce a plurality of NSAIDs or DMARDs into a hyaluronic acid functional group for introducing NSAIDs or DMARD, for example, one carboxyl group.
- polyvalent spacer compounds examples include serinol and its derivatives, serine derivatives, threonine derivatives, 2-amino-1,5-pentanediol and its derivatives, 3-amino-1,2-propanediol and its derivatives, Tris (hydroxymethyl) amino methane and its derivatives, bishomotris and its derivatives, etc. are mentioned.
- the advantage of using this polyvalent spacer compound is that it is possible to introduce more NSAIDs or DMARDs without involving many of the lipoxyl and hydroxyl groups that contribute to the hydrophilicity of hyaluronic acid in the substitution reaction. Many NSAIDs or DMARDs have been introduced because they can Nevertheless, it is possible to maintain hydrophilicity, that is, solubility in an aqueous medium more.
- the method for synthesizing the substance of the present invention is not particularly limited as long as it is a method capable of obtaining the soluble substance of the present invention as described above.
- a carboxyl group or a hydroxyl group of the hyaluronic acid participates in the binding of the compound. Decrease in hydrophilicity.
- An example of a method for synthesizing the substance 1 of the present invention is characterized in that alkali treatment is performed after an introduction reaction for introducing NSAIDs into hyaluronic acid via a spacer having a site that can be degraded in vivo. Method.
- the alkali treatment for making the reaction solution alkaline after the introduction reaction is not particularly limited as long as the solution becomes alkaline. Specifically, a method in which either an organic base or an inorganic base is added to the solution is exemplified, but in consideration of the subsequent treatment and the like, an inorganic base is preferred. Furthermore, even among inorganic bases, weak bases such as sodium bicarbonate and sodium carbonate are less likely to affect hyaluronic acid and NSAIDs than strong bases such as sodium hydroxide. This is desirable.
- the pH condition of the alkali treatment here is, for example, 7.2-11, preferably 7.5-10.
- the treatment time of the alkali treatment is not particularly limited as long as it does not affect the reduction of molecular weight of hyaluronic acid, and includes 2 to 12 hours, preferably 2 to 6 hours.
- a soluble hyaluronic acid derivative can be obtained without affecting the acid.
- a weak alkali such as sodium bicarbonate is added to the reaction solution, followed by stirring for several hours, followed by neutralization and ethanol precipitation.
- the desired soluble hyaluronic acid derivative can be obtained by post-treatments such as drying and the like.
- the above method can be applied to the synthesis of the substance 2 of the present invention, and the soluble substance 2 of the present invention can be obtained.
- the method of introducing spacers and NSAIDs or DMARDs into hyaluronic acid is as follows. After introducing the spacers into hyaluronic acid, the NSAIDs or DMSA are added to the spacer-bound hyaluronic acid. Can be either a method of introducing DMARD or a method of introducing a spacer into NSAIDs or DMARD in advance and then introducing the spacer-bonded NSAIDs or the spacer-coupled DMARD into hyaluronic acid. The latter method is more desirable.
- the method of binding NSAIDs or DMARD, hyaluronic acid and spacer is not particularly limited.
- any method capable of achieving an ester bond, an amide bond, a thioester bond, or the like can be used.
- a commonly used ordinary method can be used, and a person skilled in the art can appropriately judge and select the reaction conditions.
- the binding of hyaluronic acid to spacer-bonded NSAIDs or spacer-bonded DMARDs or spacer compounds is achieved by using either the carboxyl group or the hydroxyl group of hyaluronic acid.
- a carboxyl group can be achieved more easily due to the high reactivity of the functional group.
- a water-soluble carbodiimide or the like for example, ethyl- 3 ( 3 -dimethylaminopropyl) carbodiimide hydrochloride
- Examples thereof include a method using a condensation auxiliary such as (HOSu) and N-hydroxybenzotriazole (HOBt) and the above-mentioned condensing agent, an active ester method, an acid anhydride method and the like.
- a method using a water-soluble condensing agent, or a method using a condensing aid and a water-soluble condensing agent is preferred as the reaction in the presence of an aqueous solvent, particularly from the viewpoint of suppressing side reactions. It is more preferable to use a force-condensing auxiliary and a water-soluble condensing agent.
- the bond between the carboxyl group of such hyaluronic acid and the spacer-bonded NSAIDs or spacer-bonded DMARD or spacer compound is formed by an ester bond or an amide bond, preferably by an amide bond. More preferably, this is done.
- the rate of introduction of NSAIDs or DMARDs into hyaluronic acid in the substance of the present invention is determined by the amount of condensing agent, condensation auxiliary agent, spacer-bound NSAIDs or spacer-bound DMARD in the synthesis step of the substance of the present invention. It can be adjusted by changing.
- the introduction rate can be measured by a method using absorbance measurement, HPLC, NMR, or the like.
- the introduction rate of DMARD is not particularly limited, but is preferably 5 to 50 mol%, more preferably 0.1 to 80 mol% per repeating disaccharide unit of hyaluronic acid.
- the appropriate introduction rate is determined in consideration of the effective concentration of NSAIDs or DMARD in the affected area or the efficiency of sustained release.
- NSAIDs or DMARDs As one of means for solving this problem, by using a polyvalent spacer compound, it becomes possible to introduce many NSAIDs or DMARDs while maintaining hydrophilicity.
- NSAIDs are introduced into all three hydroxyl groups, three molecules of NSAIDs will be introduced into one spacer molecule.
- the aminotriol-bound NSAIDs have a substitution rate of, for example, 20% for the carboxyl group of hyaluronic acid (substitution rate per unit of hyaluronic acid disaccharide)
- a hyaluronic acid derivative having a hyaluronic acid-constituting disaccharide unit represented by the following formula (1) is given as a specific preferable embodiment of the substance 1 of the present invention.
- the following formula (1) indicates that the portion per hyaluronic acid-constituting disaccharide unit in which N-acetyl-D-darcosamine, into which an anti-inflammatory compound is introduced, and D-glucuronic acid are ⁇ -1,3 bonded. Show the structure.
- ⁇ —CO— represents one residue of the constituent disaccharide unit of hyaluronic acid
- R 2 represents the NSAID residue or hydrogen atom represented by Z—CO— (unless all are hydrogen atoms)
- -HN- R 1 — (O—) n is a spacer represented by HN— R 1 — (OH) n having n hydroxyl groups
- R 1 represents a linear or branched hydrocarbon group having 2 to 12 carbon atoms which may have a substituent
- CO—NH— is a constituent of hyaluronic acid.
- the amide bond between the carboxyl group of the glucuronic acid sugar and the amino group of the spacer compound is shown, and -O-CO- shows the ester bond between the hydroxyl group of the spacer compound and the carboxyl group of the NSAID.
- n represents an integer of 1 to 3.
- the carboxyl group in the hyaluronic acid residue constituting the hyaluronic acid derivative forms an amide bond involved in the bond with the spacer-bonded anti-inflammatory compound residue according to the introduction rate of the NSAID residue. , Or not involved !, as free carboxyl groups.
- R 1 an alkyl group, Aruke - group, Ariru group, an alkoxyl group, Ashiru group, carboxyl group, halogen and the like, alkyl groups, Aruke - group, an alkoxyl group, Ashiru group Is preferably 11 to 11, more preferably 114, and the aryl group is preferably a phenyl group.
- a spacer compound having a carboxyl group as a substituent includes serine
- a spacer compound having a carboxyl group and a methyl group includes threonine.
- Y—COOH represents one disaccharide unit constituting hyaluronic acid before the reaction
- HN—R 1 — (OH) n represents a spacer compound before the reaction.
- HOOC—Z reacts
- the most suitable method for synthesizing the disaccharide unit constituting the hyaluronic acid represented by the above formula (1) is a method in which a spacer compound is bound to an NSAID and then reacted with hyaluronic acid. This reaction is conceptually represented as follows.
- R 7 represents a protecting group of the Amino group, the protecting group, usually is for a protecting group of the Amino group, it is possible to use a protecting group Ru Do particularly limited, but, tert-butoxy Carbonyl, benzyloxycarbol, 9 fluorenylmethyloxycarbol And an acyl-type protecting group such as a formyl group and a phthaloyl group, and more preferably a urethane-type protecting group.
- RR 2 and Z are as defined above.
- R 1 is hydrocarbon of a linear or hydrocarbon group having 2 or C even more preferred instrument 3 having a branch of a good carbon number 2 5 may have a substituent
- a hydrogen group is preferred, for example, an ethylene group, a trimethylene group or a propylene group.
- the NSAID used in the above equation (1) can be selected from the NSAIDs described above. Further, a compound represented by the following formula (7) is preferably mentioned.
- R 8 is a lower alkyl group and a substituted group or a hydrogen atom is selected from lower alkoxy groups, and more preferably a lower alkyl group or a hydrogen atom good carbon number of 1 one 12 be branched Among them, a lower alkyl group having 14 to 14 carbon atoms or a hydrogen atom is more preferable.
- X 1 and X 2 each independently represent a substituent or a halogen atom selected from a lower alkyl group and a trifluoromethyl group, and at least one of them is a halogen atom.
- R 8 is preferably bonded to the 5-position when the carboxymethyl group is 1-position and the amino residue is 2-position in the benzene ring to which R 8 is bonded.
- Typical examples of the compound represented by the above formula (7) include compounds represented by the following formulas (8) and (9). [0092] [Formula 5]
- the diclofunac-introduced hyaluronic acid derivative has a very powerful analgesic action and anti-inflammatory action.
- Hyaluronic acid having a weight average molecular weight of 50,000 to 3,000,000 is preferred as the hyaluronic acid which can be used for the substance of the present invention having the disaccharide unit constituting hyaluronic acid represented by the above formula (1).
- Hyaluronic acid having an average molecular weight of 50,000-2,000,000 is more preferably selected.
- the substance of the present invention having a disaccharide unit constituting hyaluronic acid represented by the above formula (1)
- a major feature of the substance of the present invention is that the substance of the present invention is soluble in an aqueous solvent, that is, it is easily water-soluble. Dissolves without any solubilization treatment. Even if the introduction rate is high, for example, 5% or more, and even 10% or more, it can be dissolved. Therefore, the solution obtained by dissolving the substance of the present invention in an aqueous medium is in a liquid form capable of being injected, and has a property of passing through a filtration filter.
- a highly hydrophobic hyaluronic acid such as NSAIDs or DMARD is introduced into a highly hydrophilic hyaluronic acid, and when a drug is introduced, the hydrophobicity of the hyaluronic acid molecule itself increases. It is known to be in the form of a gel or an insoluble material having high viscoelasticity, and is unsuitable as an injection which is extruded from an injection device.
- the substance of the present invention can be a transparent solution having a passability through a filtration filter because the solubility of the hyaluronic acid derivative is maintained by performing an alkali treatment in the production process as described above, for example. .
- the solution of the substance of the present invention can be filtered by a filter, and dust removal, bacteria elimination, and sterilization by the filter filtration can be performed. That is, dust and bacteria can be removed by passing through a 5 ⁇ m or 0.45 ⁇ m filter, and more preferably through a 0.22 m filter, and sterilization is possible.
- a solution obtained by dissolving the substance of the present invention at 1.0% by weight in an aqueous medium is mixed with a porous filter (pore size (pore size) under a temperature condition of 24 ° C and a pressure of 5.0 kgZcm 2. It is preferable that 2 mL or more can pass through 0.45 ⁇ m, diameter 25 mm) per minute.
- a solution obtained by dissolving the substance of the present invention at 1.0% by weight in an aqueous medium passes through a porous filter (pore size (pore size) 0.22 m, diameter 25 mm) at least 2 mL per minute under the same conditions as above. It is even more preferred that it is possible.
- the agent of the present invention contains a hyaluronic acid derivative of the present invention as an active ingredient It is a drug.
- the drug of the present invention can take a form that can be extruded with an injection device (injection device) or the like, utilizing the above-mentioned properties of the material of the present invention, and is also used as a solution in which the material of the present invention is dissolved in an aqueous medium. Is done.
- a solution having a concentration of the substance of the present invention of 0.1% by weight to 10% by weight using physiological saline, phosphate-buffered saline or water for injection as a solvent which can be administered in vivo is mentioned. This solution is preferably clear and not cloudy.
- the agent of the present invention can remove dust, remove bacteria, and sterilize by filter filtration.
- Dust and bacteria can be removed by passing through a 5 ⁇ m or 0.45 ⁇ m filter, and sterilization can be achieved by passing through a 0.22 m filter.
- the drug of the present invention can be used in combination with the substance of the present invention and a pharmaceutically acceptable carrier as long as the advantage of the drug of the present invention that it can be sterilized by filtration is not impaired.
- the agent of the present invention thus prepared can be applied to sterilization by filtration, and has a certain degree of viscoelasticity, and is preferably in a state of being in a state of being viscous.
- the drug of the present invention can be used as a drug for parenteral administration or a drug for topical administration.
- Preferred forms for parenteral administration and topical administration include administration methods such as injection and infusion, which preferably employ the above-mentioned solution of the substance of the present invention in an aqueous solvent. May also include "injection").
- An extruder used for injection, injection, or the like can use a commonly used device such as a syringe or an injecting device for the purpose of administering a filled drug by extruding it. It is.
- kits in which the drug of the present invention or the solution of the substance of the present invention is filled in an extrudable injection tool equipped with a plunger for drug extrusion and the like.
- the kit fills a syringe with a solution of the substance of the present invention in a pharmaceutically acceptable phosphate buffered saline, physiological saline or water for injection, and is slidable with a plunger for drug extrusion.
- the plunger for drug extrusion is It is formed of an elastic body such as a force rubber or a synthetic rubber which can use a commonly used one, and is slidably inserted into the syringe in a tightly contacted state.
- the kit also includes a plunger rod for pushing the plunger and pushing out the medicine!
- the target disease and the administration route of the drug of the present invention are not particularly limited, but a therapeutic agent for the treatment of arthropathy, suppression of inflammation and pain (hereinafter also referred to as the therapeutic agent of the present invention) ) Can be used, which is preferable.
- the term “therapeutic agent” also includes agents used for the purpose of prophylaxis and alleviation of symptoms, which are not limited to “therapeutic agents” used only for treatment.
- the therapeutic agent of the present invention is useful for the treatment of arthrosis, which has only a sustained-release action of an anti-inflammatory compound such as NSAIDs or a drug delivery system (Drug Delivery System) action as described below, in addition to the therapeutic effect of the anti-inflammatory compound.
- an anti-inflammatory compound such as NSAIDs or a drug delivery system (Drug Delivery System) action as described below
- drug delivery system Drug Delivery System
- the effect on arthropathy of the hyaluronic acid preparation currently used in the clinic can be expected at the same time.
- the dose of the therapeutic agent of the present invention exhibits the most appropriate therapeutic effect according to the administration route, administration form, purpose of use, specific symptoms, age, body weight, etc. of the animal to be administered. This is a matter that must be determined individually and is not particularly limited.
- the hyaluronic acid derivative may be about 1 mg to 1,000 mg, preferably about 5 mg to 500 mg, more preferably about 10 mg to 100 mg per adult.
- the strength of the NSAIDs or DMARD used in the substance of the present invention which is an active ingredient, is considered to greatly affect the strength of the action of the therapeutic agent of the present invention,
- the range is not always suitable and needs to be set in consideration of the dose converted to NSAIDs or DMARD alone. Further, as shown in the examples described below, the drug of the present invention
- NSAIDs are administered alone, they are stably and continuously present at the administration site, so it is necessary to consider this point.
- the site to which the therapeutic agent of the present invention is applied is not particularly limited as long as it can be administered by parenteral administration, and knee joints, shoulder joints, hip joints, temporomandibular joints and the like, which are preferably joints, are particularly preferred.
- knee osteoarthritis (OA) and rheumatic knee arthritis (RA) is particularly preferred.
- an appropriate concentration as an injection (injection) agent into a joint can be appropriately selected as described above, but the concentration of the solution is 0.3%. — 3.0% by weight is preferred 0.5—1.5% by weight is more preferred
- Spacer and bonding form: aminoalkyl alcohol NSAID and ester bond, hyaluronic acid and amide bond
- NSAID hyaluronic acid disaccharide unit per 5- 50 mole 0/0
- Supplied condition The syringe is filled in a sterile condition.
- NSAID diclofenac or a derivative thereof is more preferable among the compounds represented by the above formulas (8) and (9), wherein the compound represented by the above formula (7) is more preferable. Is more preferred,.
- Aminopropyl alcohol or aminoethyl alcohol is more preferably selected as the spacer.
- the introduction rate is more preferably 10 to 50 mol% per hyaluronic acid disaccharide unit.
- a 5 ⁇ m or 0.45 ⁇ m filter can be filtered, and further a 0.22 ⁇ m filter can be filtered.
- the agent of the present invention is particularly preferably used as a therapeutic agent for arthropathy, particularly as a joint injection for treating arthropathy.
- a therapeutic agent for arthropathy particularly as a joint injection for treating arthropathy.
- these compounds immediately pass through the synovium and enter the blood, so that a large effect cannot be expected.
- the agent of the present invention shows resistance to in vivo degradation due to the binding between NSAIDs and a spacer compound, the binding force between hyaluronic acid and a spacer compound. Further, it is preferable that the binding portion between the NSAIDs and the spacer compound is not decomposed in the joint cavity, but is taken up by the synovium and decomposed in the synovial tissue. By changing the binding mode between NSAIDs and spacer compounds and between hyaluronic acid and spacer compounds, it is possible to change the resistance to biodegradation, thereby controlling the ease and rate of release. It works.
- ester bonds are more susceptible to degradation than amide bonds. For this reason, if a spacer is selected that binds to hyaluronic acid with an amide bond and NSAIDs with an ester bond, the substance of the present invention, which has been hydrolyzed or immediately hydrolyzed at the ester bond, will release NSAIDs and act. become.
- the drug of the present invention can be formulated as a sustained release formulation.
- the drug of the present invention releases NSAIDs at the site of action. It is clearly assumed that is more preferred.
- the substance of the present invention is a low molecular weight compound, it is known that, when administered alone, in vivo metabolism is rapid and difficult to efficiently deliver to a target site (cell). It is also useful as a drug delivery system (DDS) substrate.
- DDS drug delivery system
- the NSAIDs or DMARD-introduced hyaluronic acid derivatives of the present invention are delivered to the target cells, are further taken up in the cells, and are continuously present at the target site, and the effects of metabolism are exerted. Is very important to reduce the effect and obtain an efficient effect.
- a therapeutically effective amount of the drug is more efficiently maintained at the administration site than in the case of single administration of the drug, so that a much smaller and much stronger therapeutic effect can be expected than in the case of oral administration.
- the sustained release of the effect and the sustainability of the effect can be improved, the number of administrations can be expected to decrease in clinical practice.
- hyaluronic acid and sodium hyaluronate were all manufactured by Seikagaku Corporation.
- PBS phosphate buffered saline
- a PBS in which a test substance was dissolved at 1.0% by weight was prepared.
- Example 2 (HOSu) aqueous solution (0.25 mL), lmol / L WSCI'HCl aqueous solution (0.25 mL), and 0.5 M aminopropanol-ketoprofen hydrochloride aqueous solution (0.5 mL) obtained in Example 1 were sequentially added, followed by stirring all day and night. 3 mL of a 5% aqueous sodium hydrogen carbonate solution was added to the reaction solution, and the mixture was stirred for 3 hours and 20 minutes. The reaction mixture was neutralized with 86 L of 50% acetic acid in syrup, 800 mg of sodium chloride was added, and the mixture was stirred. The precipitate was added to 200 mL of ethanol and precipitated.
- the precipitate was washed twice with 80% ethanol, twice with ethanol, and twice with ethyl ether, and dried under reduced pressure at room temperature overnight. 198 mg of a white solid were obtained.
- the introduction rate of ketoprofen by HPLC was 15.5%.
- the obtained substance was dissolved in PBS to a concentration of 1.0% by weight to prepare a solution.
- the solution was a colorless and transparent liquid, and the filter penetration test was "A".
- Boc-aminopropanol ibuprofen obtained above was dissolved in 1 mL of dichloromethane, and 4 mL of 4 M HCl / ethyl acetate was added under ice-cooling, and the mixture was cooled for 10 minutes under ice-cooling and at room temperature for 3 hours. Stirred. After confirming the disappearance of Boc-aminopropanol ibuprofen by TLC, getyl ether was added and decanted three times. Then, it was dried under reduced pressure to give the title substance in a yield of 406 mg.
- Boc-aminopropanol (2.11 mmol), acetylsalicylic acid (2.11 mmol) (manufactured by Wako Pure Chemical Industries, Ltd.), and DMAP (0.42 mmol) were added to dichloromethane dioxane.
- Boc-aminopropanol-acetylsalicylic acid (0.814 mmol) obtained above was dissolved in dichloromethane (1 ml), and the solution was cooled with ice to give 4N hydrochloric acid and ethyl acetate.
- Hyaluronic acid with a weight average molecular weight of 900,000 (100 mg) 0.25 mmol Z disaccharide unit is dissolved in water dioxane (1: 1), 2 mol / L HOSu (0.1 ml), lmol / L
- the introduction rate of acetylsalicylic acid according to the spectrophotometry was 13.5%.
- the obtained substance was dissolved in PBS to a concentration of 1.0% by weight to prepare a solution.
- the solution was a colorless and transparent liquid, and the filter passage test was "A".
- Boc-aminopropanol felbinac (1.69 mmol) obtained above was dissolved in dichloromethane (1 ml), and 4N hydrochloric acid Z-ethyl acetate (3 ml) was added under ice cooling. The mixture was returned to room temperature and stirred for 2 hours. After confirming the disappearance of Boc-aminopropanol felbinac by TLC, getyl ether was removed and the resulting precipitate was centrifuged. The obtained precipitate was decanted three times with getyl ether, and dried under reduced pressure to give the title compound.
- Hyaluronic acid with a weight average molecular weight of 900,000 (200 mg) 0.5 mmol Z disaccharide unit is dissolved in water dioxane (1: 1, 45 ml) and 2 mol / L HOSu
- Example 12 lmol / L WSCI-HC1 (0.25 ml), and a 0.5M aqueous solution of panpinamine hydrochloride (0.5 ml) obtained in Example 12 were added and stirred for one day.
- 5% aqueous sodium hydrogencarbonate solution 5% aqueous sodium hydrogencarbonate solution
- Boc-aminopropanol-fenbufen (1.82 mmol) obtained above is dissolved in dichloromethane (4 ml), and 4N hydrochloric acid in ethyl acetate under ice cooling.
- Hyaluronic acid with a weight average molecular weight of 900,000 (200 mg) After dissolving in 0.5 mmol Z disaccharide unit of water dioxane (1: 1, 45 ml), 2 mol / L HOSu
- Boc-aminopropanol (0.616 mmol), mephenamic acid (0.620 mmol) (manufactured by Wako Pure Chemical Industries, Ltd.), DMAP (0.126 mmol) in dichloromethane
- Boc-aminopropanol-mephenamic acid (0.462 mmol) obtained above was dissolved in dichloromethane (0.5 ml), and 4N hydrochloric acid Z ethyl acetate (1.5 ml) was added under ice cooling.
- Aromatic 7.09 (1H, t, Aromatic), 7.14 (1H, d, Aromatic), 7.22-7.25 (1H, m, Aromatic), 7.92 (1H, dd, Aromatic), 9.17 (1H, s, -PhNHPh- )
- Hyaluronic acid with a weight average molecular weight of 900,000 (100 mg) 0.25 mmol Z disaccharide unit is dissolved in water dioxane (1: 1, 22.5 ml) and 2 mol / L HOSu
- actalit was prepared by the following synthesis method.
- Example 24 Synthesis of Aminopropanol-Ketoprofen-Introduced Sodium Hyaluronate 200 mg (0.5 mmol Z disaccharide unit) of sodium hyaluronate having a weight average molecular weight of 900,000 was dissolved in 23 mL of water, 23 mL of dioxane, and then an aqueous HOSu solution 0.3 mmolZ2mL, WSC1-HC1 aqueous solution 0.15mmolZ2mL, and the aminoaminopropanol-ketoprofen hydrochloride aqueous solution 1.5mmolZ2mL obtained in Example 1 were sequentially added, followed by stirring all day and night.
- the obtained substance was dissolved in PBS to a concentration of 1.0% by weight to prepare a solution.
- the solution was a colorless and transparent solution, and the filter passage test was "C".
- Ketoprofen (l.llmmol) construed dissolve the (Tokyo Kasei Kogyo Co., Ltd.) in dichloromethane (3ml), Toryechiruamin (l.ll mmo l), chloride-dimethyl-phosphine Back Then oil
- Boc-serinol-ketoprofen (0.428 mmol) was dissolved in dichloromethane (1 ml), 4N hydrochloric acid-Z-ethyl acetate (4 ml) was added under ice-cooling, and the mixture was gradually stirred at room temperature for 2 hours. After confirming the disappearance of Boc-serinol-ketoprofen by TLC, getyl ether and hexane were added, and the deposited precipitate was centrifuged. The obtained precipitate was dried under reduced pressure to give the title compound.
- Hyaluronic acid with a weight average molecular weight of 900,000 (100 mg) 0.25 mmol Z disaccharide unit is dissolved in water dioxane (1: 1, 22.5 ml), and 2 mol / L HOSu
- ketoprofen 92.3 mg.
- the introduction rate of ketoprofen by HPLC was 11.2%.
- the obtained substance was dissolved in PBS to a concentration of 1.0% by weight to prepare a solution.
- the solution was a colorless and transparent liquid, and the filter passage test was "A".
- Ketoprofen, 2 amino— 1,5-pentanediol), 7.40—7.80 (18H, m, Aromatic)
- Hyaluronic acid with a weight-average molecular weight of 900,000 (137 mg) 0.34 mmol Z disaccharide unit is dissolved in water dioxane (1: 1, 30.8 ml), then 2 mol / L
- the resulting precipitate was washed with an 80% aqueous ethanol solution, ethanol, and getyl ether. Dry under reduced pressure to obtain the title compound (135. Img).
- the introduction rate of ketoprofen by HPLC was 18.5%.
- the obtained substance was dissolved in PBS to a concentration of 1.0% by weight to prepare a solution.
- the solution was a colorless and transparent liquid, and the filter passage test was "A".
- Boc-amino-1,2 propanediol-ketoprofen (1.76 mmol) obtained above is dissolved in dichloromethane (1 ml), and 4N hydrochloric acid and ethyl acetate are added under ice cooling.
- Hyaluronic acid with a weight average molecular weight of 900,000 (200 mg) 0.5 mmol Z disaccharide unit is dissolved in water dioxane (1: 1, 45 ml), and 2 mol / L HOSu
- ketoprofen was introduced per one molecule of Boc-tris (hydroxymethyl) aminoaminomethane.
- Boc-glycine 131 mg (0.75 mmol) of Boc-glycine was dissolved in 1 mL of chloroform, and 105 ⁇ L of triethylamine was added under ice-cooling.
- the reaction solution was neutralized with 50% acetic acid (86 L) and then sodium chloride (1.Og) was stirred and stirred. 200 ml of ethanol was added for precipitation, and the precipitate was washed twice with 85% ethanol, twice with ethanol, and getyl ether, and dried at room temperature under reduced pressure overnight. 190.5 mg of a white solid was obtained.
- the introduction rate of diclofenac by a spectrophotometer was 17.1%.
- Inhalational anesthesia (3.0% concentration, flow rate 2.0LZmin) of isoflurane (Folene (registered trademark), manufactured by Dainippon Pharmaceutical Co., Ltd.) filled in an anesthesia machine for small animals (TK-4, manufactured by Bio Machinery) as a general anesthetic
- Rats (Crj: SD strain (SPF), male, 7 weeks old) were fixed in a dorsal position under ether anesthesia, and the left hind leg knee joint was shaved widely with a clipper. Spray and disinfect around the joint with 70% alcohol, and use a syringe with ⁇ "for 29G insulin
- bradycun BK
- prostaglandin E PGE
- the mixed solution of 22 was administered at a dose of 50 LZ joint.
- the analgesic substance solution was prepared so that the final concentrations of BK and PGE were 4 gZmL and 2 gZmL, respectively. Painful thing
- FIG. 1 shows a graph in which the pain response of each individual was scored.
- Inhalational anesthesia (3.0% concentration, flow rate 2.0 LZmin) of isoflurane (Folene (registered trademark), manufactured by Dainippon Pharmaceutical Co., Ltd.) filled in an anesthesia machine for small animals (TK-4, manufactured by Bio Machinery) as a general anesthetic
- Rats (Crj: SD strain (SPF), male, 6 weeks old) were fixed in a dorsal position under ether anesthesia, and the area around the knee joint of the left hind leg was shaved widely with a clipper. Spray and disinfect around the joint with 70% alcohol, and use a syringe with ⁇ "for 29G insulin
- KP-HA KP-HA
- the walking state of each group was visually observed using the following pain score table in which the walking state was scored under blinds. The results are shown in FIG.
- the load exerted on the silver nitrate-administered foot was measured using a limb load measuring device (manufactured by Tokken Co., Ltd.), and the result obtained by dividing the weight by the body weight was measured as the load load ratio (note that Load The load ratio was normally about 32%.) The measurement was performed once daily until 2 days after the administration of the test substance. Figure 3 shows the results.
- the ability to gradually reduce the pain score in both the HA-administered group and the KP-HA-administered group The KP-HA-administered group had a faster degree of pain reduction (recovery from pain) than the HA-administered group.
- the loading rate increases as pain returns, but the results in Fig. 3 show that the KP-HA administration group had a significantly shorter loading rate value than the HA administration group in a shorter time. I got higher.
- the correlation between the KP-HA group and the HA group in the results of FIGS. 2 and 3 was the same.
- KP-HA aminopropanol-ketoprofen-introduced sodium hyaluronate solution
- ketoprofen and HA KP + HA
- HA solution A mixed solution of ketoprofen and HA (KP + HA) dissolved in an HA solution was used as a test substance.
- test substance Each 300 L of the test substance was administered into the joint cavity from the outside of the knee of the egret knee using an L syringe. Necropsy was performed at 6, 12, 24, 2, and 4 days after administration of the test substance.
- the synovial tissue was also separated and collected from the knee joint force after collecting the synovial fluid in (2) above.
- the collected synovial tissue was thoroughly washed with 100 mL of physiological saline to completely remove the attached synovial fluid. After removing the patella from the synovial tissue, place it in a tube and add 10 mM sodium acetate solution. 5 mL of Protease K (Lot ⁇ 102.8633, manufactured by SIGMA) adjusted to a concentration of 2 mg / mL at pH 7.5 was added, and enzyme digestion was performed at 55 ° C. for 41 hours while vortexing appropriately. After digestion, the enzyme was inactivated at 100 ° C for 5 minutes, and the amount of KP in the obtained digestive juice was measured by the following procedure.
- KP single agent
- KP + HA mixture
- KP-HA conjugate
- KP was present in both synovial fluid and synovial tissue even after 4 days. It is presumed that KP is persistently present at the administration site and has a sustained effect.
- Example 46 Effect of Intra-articular Administration of Aminobrono V—Rucloclofenac-Introduced Sodium Hyaluronate with Different Introduction Rate (DS) to Rat 1% Silver Nitrate-Induced Pain Model
- Aminobrono V Rucloclofenac-Introduced Sodium Hyaluronate with Different Introduction Rate (DS) to Rat 1% Silver Nitrate-Induced Pain Model
- Example 44 As in Example 44, the walking state of each group was visually observed using a pain score table in which the walking state was scored under blinds. The results are shown in FIG. The results are shown by mean pain score standard deviation, with DS18%, DS10% and DS4% corresponding to DS18.2%, DS9.7% and DS4.3%, respectively.
- * indicates that there is a significant difference with respect to PBS at a risk rate of 0.01 ⁇ p ⁇ 0.05
- ** indicates that there is a significant difference with respect to PBS at a risk rate of p ⁇ 0.01.
- test substance DS 18.2%, DS 9.7% and DS 4.3%
- All sodium aluronate derivatives showed an analgesic effect.
- test substances of DS 18.2% and DS 9.7% showed a dramatic analgesic effect as compared with PBS.
- analgesic effect improved depending on the increase in the introduction rate (DS) of diclofenac.
- test substance was orally administered at a dose of 1 mL / head using an oral probe for rats (Fuchigami Instrument Store).
- (0 (high dose group) is worth 50 mg / kg of diclofenac sodium.
- the GO low dose group
- diclofenac sodium is worth 1 mg / kg of diclofenac sodium, which is almost the same as the clinical dose.
- Example 46 As in Example 46, the walking state of each group was visually observed using a pain score table in which the walking state was scored under blinds. The results are shown in FIG. In Figure 6, "
- FIG. 6 shows, as a reference, the diclofenac-introduced hyaluronic acid derivative measured in Example 46 above.
- the oral administration group of the low dose group (lmg / kg), which is almost the clinical dose, showed no effect compared to the joint injection group of PBS.
- intra-articular administration of a diclofenac-introduced hyaluronic acid derivative has shown pain suppression after administration, and has side effects such as oral administration of the high dose group of diclofenac sodium (50 mg / kg). No apparent symptoms were observed, confirming high utility.
- FIG. 7 also shows the results of the diclofenac-introduced hyaluronic acid derivative (DS 18.2%) measured in Example 46 above as “Dic-HA (conjugate)” for reference.
- test was carried out according to Example 44 described above, and intra-articular administration of the following test substance was evaluated.
- aminoethanol diclofenac-introduced sodium hyaluronate solution using aminoethanol having a spacer carbon number one less than that of aminopropanol also showed a high analgesic effect.
- Diclofenac was introduced via amide bond.
- Aminopropane diclofenac-introduced sodium hyaluronate solution had no effect in the experimental system of this example.
- the analgesic effect of the diclofenac-introduced hyaluronic acid derivative using hyaluronic acid with a molecular weight of 65 kDa was reduced compared to that of the molecular weight of 800,000.
- FIGS. 9 (a) and 9 (b) The results are shown in FIGS. 9 (a) and 9 (b).
- ⁇ Diclofenac NaJ is in the aqueous solution of diclofenac sodium
- ⁇ Dic-C3-HA '' is in the aqueous solution of aminopropanol diclofenac-introduced sodium hyaluronate
- ⁇ Dic-C2-HA '' is in the aqueous solution of aminoethanol.
- HA corresponds to the above 200 ⁇ g / ml sodium hyaluronate aqueous solution.
- Enzyme activity value (%) test substance treated group ⁇ untreated group X 100
- Mycobacterium butvricum (Lot No.2115687, Difco) 6 mg / mL in an autoclave 121
- the right hind paw was injected subcutaneously at the dose of L / joint.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Rheumatology (AREA)
- Molecular Biology (AREA)
- Pain & Pain Management (AREA)
- Dermatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- Materials Engineering (AREA)
- Polymers & Plastics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Polysaccharides And Polysaccharide Derivatives (AREA)
- Steroid Compounds (AREA)
Abstract
Description
Claims
Priority Applications (12)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020067015909A KR101142583B1 (ko) | 2004-01-07 | 2005-01-07 | 히알루론산 유도체 및 그것을 포함하는 약제 |
JP2005516899A JP4792294B2 (ja) | 2004-01-07 | 2005-01-07 | ヒアルロン酸誘導体及びそれを含む薬剤 |
EP18159234.6A EP3363463A3 (en) | 2004-01-07 | 2005-01-07 | Hyaluronic acid derivative and drug containing the same |
EP05703390A EP1710257A4 (en) | 2004-01-07 | 2005-01-07 | HYALURONIC ACID DERIVATIVE AND MEDICAMENT CONTAINING THEREOF |
EP12170463.9A EP2497785B1 (en) | 2004-01-07 | 2005-01-07 | Hyaluronic acid derivative and drug containing the same |
CN2005800073232A CN1930190B (zh) | 2004-01-07 | 2005-01-07 | 透明质酸衍生物及含有其的药剂 |
CA2555759A CA2555759C (en) | 2004-01-07 | 2005-01-07 | Hyaluronic acid derivative and drug containing the same |
NZ549010A NZ549010A (en) | 2004-01-07 | 2005-01-07 | Hyaluronic acid derivative and drug containing the same |
US10/585,417 US7879817B2 (en) | 2004-01-07 | 2005-01-07 | Hyaluronic acid derivative and drug containing the same |
AU2005203988A AU2005203988B2 (en) | 2004-01-07 | 2005-01-07 | Hyaluronic acid derivative and drug containing the same |
HK07107838.4A HK1103549A1 (en) | 2004-01-07 | 2007-07-20 | Hyaluronic acid derivative and drug containing the same |
US12/971,361 US20110083991A1 (en) | 2004-01-07 | 2010-12-17 | Hyaluronic acid derivative and drug containing the same |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2004002478 | 2004-01-07 | ||
JP2004-002478 | 2004-01-07 |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US12/971,361 Continuation US20110083991A1 (en) | 2004-01-07 | 2010-12-17 | Hyaluronic acid derivative and drug containing the same |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2005066214A1 true WO2005066214A1 (ja) | 2005-07-21 |
Family
ID=34747042
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2005/000125 WO2005066214A1 (ja) | 2004-01-07 | 2005-01-07 | ヒアルロン酸誘導体及びそれを含む薬剤 |
Country Status (11)
Country | Link |
---|---|
US (2) | US7879817B2 (ja) |
EP (4) | EP2497785B1 (ja) |
JP (1) | JP4792294B2 (ja) |
KR (1) | KR101142583B1 (ja) |
CN (2) | CN1930190B (ja) |
AU (1) | AU2005203988B2 (ja) |
CA (2) | CA2750725C (ja) |
HK (2) | HK1103549A1 (ja) |
NZ (1) | NZ549010A (ja) |
RU (1) | RU2390529C2 (ja) |
WO (1) | WO2005066214A1 (ja) |
Cited By (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2007004675A1 (ja) * | 2005-07-06 | 2007-01-11 | Seikagaku Corporation | 薬剤導入光架橋ヒアルロン酸誘導体ゲル |
WO2007126154A1 (en) * | 2006-05-01 | 2007-11-08 | Seikagaku Corporation | Method of producing polysaccharide derivatives |
WO2009116509A1 (ja) * | 2008-03-18 | 2009-09-24 | 日本化薬株式会社 | 生理活性物質の高分子結合体 |
JP2010528065A (ja) * | 2007-05-28 | 2010-08-19 | ロンバルド,ヴィンチェンツォ・マッシモ | 動物運動系の領域における局所使用のための消炎及び鎮痛組成物 |
US8088916B2 (en) | 2004-03-05 | 2012-01-03 | Denki Kagaku Kogyo Kabushiki Kaisha | Hyaluronic acid-methotrexate conjugate |
US8188222B2 (en) | 2006-11-08 | 2012-05-29 | Nippon Kayaku Kabushiki Kaisha | High molecular weight derivative of nucleic acid antimetabolite |
US8323669B2 (en) | 2006-03-28 | 2012-12-04 | Nippon Kayaku Kabushiki Kaisha | Polymer conjugate of taxane |
US8334364B2 (en) | 2006-11-06 | 2012-12-18 | Nipon Kayaku Kabushiki Kaisha | High-molecular weight derivative of nucleic acid antimetabolite |
US8703878B2 (en) | 2007-09-28 | 2014-04-22 | Nippon Kayaku Kabushiki Kaisha | High-molecular weight conjugate of steroids |
US8808749B2 (en) | 2009-05-15 | 2014-08-19 | Nippon Kayaku Kabushiki Kaisha | Polymer conjugate of bioactive substance having hydroxy group |
WO2015005458A1 (ja) * | 2013-07-10 | 2015-01-15 | 生化学工業株式会社 | グリコサミノグリカン誘導体及びその製造方法 |
US8940332B2 (en) | 2006-05-18 | 2015-01-27 | Nippon Kayaku Kabushiki Kaisha | High-molecular weight conjugate of podophyllotoxins |
US9018323B2 (en) | 2010-11-17 | 2015-04-28 | Nippon Kayaku Kabushiki Kaisha | Polymer derivative of cytidine metabolic antagonist |
JP2015166394A (ja) * | 2009-10-30 | 2015-09-24 | 興和株式会社 | ロキソプロフェン又はその塩含有の医薬組成物 |
JP2015172057A (ja) * | 2010-01-25 | 2015-10-01 | ローム アンド ハース エレクトロニック マテリアルズ エルエルシーRohm and Haas Electronic Materials LLC | 窒素含有化合物を含むフォトレジスト |
US9149540B2 (en) | 2008-05-08 | 2015-10-06 | Nippon Kayaku Kabushiki Kaisha | Polymer conjugate of folic acid or folic acid derivative |
US9346923B2 (en) | 2011-09-11 | 2016-05-24 | Nippon Kayaku Kabushiki Kaisha | Method for manufacturing block copolymer |
JP2016529362A (ja) * | 2013-08-29 | 2016-09-23 | ホーリー ストーン バイオテック カンパニー リミテッド | グリコサミノグリカン化合物、その調製方法および使用 |
JP6026708B1 (ja) * | 2015-01-09 | 2016-11-16 | 生化学工業株式会社 | コンドロイチン硫酸誘導体及び膀胱疾患処置剤 |
WO2018168921A1 (ja) | 2017-03-14 | 2018-09-20 | 生化学工業株式会社 | 関節疾患処置用組成物およびこれを含むキット |
WO2018168920A1 (ja) | 2017-03-14 | 2018-09-20 | 生化学工業株式会社 | 関節疾患処置用組成物およびこれを含むキット |
WO2019182015A1 (ja) | 2018-03-22 | 2019-09-26 | 持田製薬株式会社 | 非ステロイド性抗炎症性化合物結合アルギン酸誘導体 |
WO2019189073A1 (ja) * | 2018-03-27 | 2019-10-03 | 生化学工業株式会社 | ヒアルロン酸合成促進剤、ヒアルロン酸合成促進方法、および細胞評価方法 |
WO2020101013A1 (ja) | 2018-11-16 | 2020-05-22 | 生化学工業株式会社 | 医薬組成物 |
US10675354B2 (en) | 2013-07-10 | 2020-06-09 | Seikagaku Corporation | Glycosaminoglycan derivative and method for producing same |
WO2021060351A1 (ja) * | 2019-09-25 | 2021-04-01 | 持田製薬株式会社 | NSAIDs結合アルギン酸誘導体 |
WO2021060395A1 (ja) * | 2019-09-25 | 2021-04-01 | 持田製薬株式会社 | 徐放性医薬組成物 |
TWI840445B (zh) | 2018-11-16 | 2024-05-01 | 日商生化學工業股份有限公司 | 水性組成物及其用途、注射套組、醫藥組成物及其製造方法、生成抑制方法 |
Families Citing this family (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20060099265A1 (en) * | 2003-03-20 | 2006-05-11 | Kazuhisa Shimizu | Micellar preparation containing sparingly water-soluble anticancer agent and novel block copolymer |
EP1792927B1 (en) | 2004-09-22 | 2013-03-06 | Nippon Kayaku Kabushiki Kaisha | Novel block copolymer, micelle preparation, and anticancer agent containing the same as active ingredient |
US7691364B2 (en) * | 2005-01-28 | 2010-04-06 | Bezwada Biomedical, Llc | Functionalized drugs and polymers derived therefrom |
WO2006122954A2 (en) * | 2005-05-18 | 2006-11-23 | Eurand Pharmaceuticals Limited | Antiproliferative conjugates comprising hyaluronic acid and n-derivatives of glutamic acid |
JP2009508852A (ja) * | 2006-01-23 | 2009-03-05 | クワンジュ インスティチュート オブ サイエンス アンド テクノロジー | 薬理活性物質と粘膜粘着性高分子とが共有結合されたコンジュゲート及びこれを用いた薬理活性物質の経粘膜運搬方法 |
US8378064B2 (en) | 2006-05-19 | 2013-02-19 | Trustees Of Boston University | Hydrophilic polymers as medical lubricants and gels |
JP5548364B2 (ja) * | 2006-10-03 | 2014-07-16 | 日本化薬株式会社 | レゾルシノール誘導体の高分子結合体 |
EP2269665B1 (en) * | 2008-05-01 | 2017-05-17 | Terumo Kabushiki Kaisha | Visible medical treatment material |
JP5683957B2 (ja) * | 2008-09-30 | 2015-03-11 | 電気化学工業株式会社 | 光安定化された医薬組成物 |
US8273725B2 (en) | 2009-09-10 | 2012-09-25 | Genzyme Corporation | Stable hyaluronan/steroid formulation |
FR2958646B1 (fr) | 2010-04-07 | 2012-05-18 | Adocia | Polysaccharides comportant des groupes fonctionnels carboxyles substitues par un derive d'acide hydrophobe. |
WO2011130476A2 (en) * | 2010-04-16 | 2011-10-20 | The Research Foundation Of State University Of New York | Polymer-based therapeutic agents |
EP2569015A1 (en) | 2010-05-14 | 2013-03-20 | Iberhospitex S.A. | Compounds for the synthesis of biostable polyurethane, polyurea or polyurea urethane polymers |
CN102399295B (zh) | 2010-09-09 | 2013-11-06 | 常州百瑞吉生物医药有限公司 | 低巯基化改性度生物相容高分子巯基化衍生物及其交联材料和用途 |
US20130344023A1 (en) * | 2011-01-24 | 2013-12-26 | Flex-Biomedical | Polymer-active agent conjugates |
IT1407868B1 (it) * | 2011-02-15 | 2014-05-16 | Fidia Farmaceutici | "medicazioni assorbenti ad attivita' antidolorifica" |
ES2667854T3 (es) * | 2011-07-07 | 2018-05-14 | Holy Stone Healthcare Co., Ltd. | Composición para uso en el tratamiento y la prevención de trastornos relacionados con la inflamación |
JP6275044B2 (ja) * | 2012-09-05 | 2018-02-07 | 中外製薬株式会社 | アミノ酸およびステリル基が導入されたヒアルロン酸誘導体 |
EP3988121A1 (en) | 2014-02-27 | 2022-04-27 | Synartro AB | Hyaluronan conjugates with pharmaceutically active substances, methods and compositions |
US11253540B2 (en) * | 2015-05-29 | 2022-02-22 | Seikagaku Corporation | Composition including glycosaminoglycan derivative and chemokine receptor activity regulator |
CN108524948B (zh) * | 2018-07-13 | 2020-03-10 | 吉林大学 | 一种透明质酸衍生化的非甾体抗炎抗癌药物及其制备方法和应用 |
CN111732675A (zh) * | 2020-08-18 | 2020-10-02 | 山东华熙海御生物医药有限公司 | 透明质酸-氨基葡萄糖接枝共聚物、制法及其应用 |
CN115466339A (zh) * | 2022-05-13 | 2022-12-13 | 宁波格鲁康生物科技有限公司 | 生物安全注射用改性透明质酸、制备方法及其在美容注射材料上的应用 |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS6264802A (ja) * | 1985-07-08 | 1987-03-23 | フイデイ−ア・ソシエタ・ペル・アチオニ | 新規多糖類エステルおよびその塩 |
JPS63105003A (ja) * | 1986-10-13 | 1988-05-10 | フィディーア・ソシエタ・ペル・アチオニ | ヒアルロン酸の架橋エステル |
WO1992006714A1 (en) * | 1990-10-18 | 1992-04-30 | Shiseido Co., Ltd. | Combination of hyaluronic acid with medicinal ingredient and production thereof |
JPH0672893A (ja) * | 1992-07-30 | 1994-03-15 | Seikagaku Kogyo Co Ltd | 抗リウマチ剤 |
JPH09188705A (ja) * | 1995-11-07 | 1997-07-22 | Seikagaku Kogyo Co Ltd | グリコサミノグリカン誘導体およびその製造法 |
WO1999059603A1 (fr) * | 1998-05-20 | 1999-11-25 | Chugai Seiyaku Kabushiki Kaisha | Medicaments contre les affections articulaires lies a l'acide hyaluronique |
Family Cites Families (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2181449B1 (ja) * | 1972-04-25 | 1975-11-28 | Synthelabo | |
DE3240758A1 (de) * | 1982-11-04 | 1984-05-10 | Siemens AG, 1000 Berlin und 8000 München | Flammgeschuetzte gehaeuse fuer kabelverbindungen der nachrichten- und energieuebertragung |
US4937270A (en) | 1987-09-18 | 1990-06-26 | Genzyme Corporation | Water insoluble derivatives of hyaluronic acid |
DK110188D0 (da) * | 1988-03-02 | 1988-03-02 | Claus Selch Larsen | High molecular weight prodrug derivatives of antiinflammatory drugs |
EP0416250A3 (en) * | 1989-08-01 | 1991-08-28 | The Research Foundation Of State University Of New York | N-acylurea and o-acylisourea derivatives of hyaluronic acid |
US5356883A (en) * | 1989-08-01 | 1994-10-18 | Research Foundation Of State University Of N.Y. | Water-insoluble derivatives of hyaluronic acid and their methods of preparation and use |
CA2061703C (en) * | 1992-02-20 | 2002-07-02 | Rudolf E. Falk | Formulations containing hyaluronic acid |
GB9112721D0 (en) | 1991-06-13 | 1991-07-31 | Smithkline Beecham Plc | Novel treatment |
US5616568A (en) * | 1993-11-30 | 1997-04-01 | The Research Foundation Of State University Of New York | Functionalized derivatives of hyaluronic acid |
PT796090E (pt) * | 1994-12-16 | 2003-07-31 | Elan Drug Delivery Ltd | Microparticulas reticuladas e sua utilizacao como veiculos terapeuticos |
IT1281876B1 (it) * | 1995-05-10 | 1998-03-03 | Fidia Advanced Biopolymers Srl | Acido ialuronico e suoi derivati esterei per la preparazione di matrici per il rilascio controllato di farmaci. |
JP4006039B2 (ja) * | 1995-09-13 | 2007-11-14 | 生化学工業株式会社 | 光架橋ヒアルロン酸コンタクトレンズ |
EP0763754B1 (en) * | 1995-09-13 | 2003-01-08 | Seikagaku Kogyo Kabushiki Kaisha (Seikagaku Corporation) | Photocured crosslinked-hyaluronic acid contact lens |
CO4960662A1 (es) | 1997-08-28 | 2000-09-25 | Novartis Ag | Ciertos acidos 5-alquil-2-arilaminofenilaceticos y sus derivados |
ITPD980169A1 (it) * | 1998-07-06 | 2000-01-06 | Fidia Advanced Biopolymers Srl | Ammidi dell'acido ialuronico e dei suoi derivati e processo per la loro preparazione. |
US6429223B1 (en) * | 2000-06-23 | 2002-08-06 | Medinox, Inc. | Modified forms of pharmacologically active agents and uses therefor |
WO2002009792A1 (en) * | 2000-07-28 | 2002-02-07 | Anika Therapeutics, Inc. | Bioabsorbable composites of derivatized hyaluronic acid |
DE60117502T2 (de) * | 2000-12-19 | 2006-08-24 | Seikagaku Corp. | Photohärtbare Derivate von Hyaluronsäure, Verfahren zu deren Herstellung, vernetztes und photogehärtetes Derivat der Hyaluronsäure und diese enthaltendes medizinisches Material |
JP4172176B2 (ja) * | 2000-12-19 | 2008-10-29 | 生化学工業株式会社 | 光反応性ヒアルロン酸およびその製造方法ならびに光架橋ヒアルロン酸および医用材料 |
US7163958B2 (en) * | 2002-07-03 | 2007-01-16 | Nitromed Inc. | Nitrosated nonsteroidal antiinflammatory compounds, compositions and methods of use |
SG178721A1 (en) * | 2003-07-29 | 2012-03-29 | Signature R & D Holdings Llc | Amino acid prodrugs |
-
2005
- 2005-01-07 CA CA2750725A patent/CA2750725C/en active Active
- 2005-01-07 EP EP12170463.9A patent/EP2497785B1/en active Active
- 2005-01-07 WO PCT/JP2005/000125 patent/WO2005066214A1/ja active Application Filing
- 2005-01-07 EP EP05703390A patent/EP1710257A4/en not_active Withdrawn
- 2005-01-07 CA CA2555759A patent/CA2555759C/en active Active
- 2005-01-07 JP JP2005516899A patent/JP4792294B2/ja active Active
- 2005-01-07 AU AU2005203988A patent/AU2005203988B2/en active Active
- 2005-01-07 CN CN2005800073232A patent/CN1930190B/zh active Active
- 2005-01-07 RU RU2006128737/04A patent/RU2390529C2/ru active
- 2005-01-07 EP EP14163923.7A patent/EP2754454A3/en not_active Withdrawn
- 2005-01-07 KR KR1020067015909A patent/KR101142583B1/ko active IP Right Grant
- 2005-01-07 EP EP18159234.6A patent/EP3363463A3/en not_active Withdrawn
- 2005-01-07 NZ NZ549010A patent/NZ549010A/en unknown
- 2005-01-07 US US10/585,417 patent/US7879817B2/en active Active
- 2005-01-07 CN CN201010243292.3A patent/CN101921347B/zh active Active
-
2007
- 2007-07-20 HK HK07107838.4A patent/HK1103549A1/xx unknown
-
2010
- 2010-12-17 US US12/971,361 patent/US20110083991A1/en not_active Abandoned
-
2011
- 2011-06-15 HK HK11106141.2A patent/HK1152055A1/xx unknown
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS6264802A (ja) * | 1985-07-08 | 1987-03-23 | フイデイ−ア・ソシエタ・ペル・アチオニ | 新規多糖類エステルおよびその塩 |
JPS63105003A (ja) * | 1986-10-13 | 1988-05-10 | フィディーア・ソシエタ・ペル・アチオニ | ヒアルロン酸の架橋エステル |
WO1992006714A1 (en) * | 1990-10-18 | 1992-04-30 | Shiseido Co., Ltd. | Combination of hyaluronic acid with medicinal ingredient and production thereof |
JPH0672893A (ja) * | 1992-07-30 | 1994-03-15 | Seikagaku Kogyo Co Ltd | 抗リウマチ剤 |
JPH09188705A (ja) * | 1995-11-07 | 1997-07-22 | Seikagaku Kogyo Co Ltd | グリコサミノグリカン誘導体およびその製造法 |
WO1999059603A1 (fr) * | 1998-05-20 | 1999-11-25 | Chugai Seiyaku Kabushiki Kaisha | Medicaments contre les affections articulaires lies a l'acide hyaluronique |
Non-Patent Citations (1)
Title |
---|
See also references of EP1710257A4 * |
Cited By (65)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8088916B2 (en) | 2004-03-05 | 2012-01-03 | Denki Kagaku Kogyo Kabushiki Kaisha | Hyaluronic acid-methotrexate conjugate |
WO2007004675A1 (ja) * | 2005-07-06 | 2007-01-11 | Seikagaku Corporation | 薬剤導入光架橋ヒアルロン酸誘導体ゲル |
US8354392B2 (en) | 2005-07-06 | 2013-01-15 | Seikagaku Corporation | Drug-introduced photo-crosslinked hyaluronic acid derived gel |
US8323669B2 (en) | 2006-03-28 | 2012-12-04 | Nippon Kayaku Kabushiki Kaisha | Polymer conjugate of taxane |
WO2007126154A1 (en) * | 2006-05-01 | 2007-11-08 | Seikagaku Corporation | Method of producing polysaccharide derivatives |
JP2007297542A (ja) * | 2006-05-01 | 2007-11-15 | Seikagaku Kogyo Co Ltd | 多糖誘導体の製造方法 |
US8557986B2 (en) | 2006-05-01 | 2013-10-15 | Seikagaku Corporation | Method of producing polysaccharide derivatives |
US8940332B2 (en) | 2006-05-18 | 2015-01-27 | Nippon Kayaku Kabushiki Kaisha | High-molecular weight conjugate of podophyllotoxins |
US8334364B2 (en) | 2006-11-06 | 2012-12-18 | Nipon Kayaku Kabushiki Kaisha | High-molecular weight derivative of nucleic acid antimetabolite |
US8188222B2 (en) | 2006-11-08 | 2012-05-29 | Nippon Kayaku Kabushiki Kaisha | High molecular weight derivative of nucleic acid antimetabolite |
JP2010528065A (ja) * | 2007-05-28 | 2010-08-19 | ロンバルド,ヴィンチェンツォ・マッシモ | 動物運動系の領域における局所使用のための消炎及び鎮痛組成物 |
USRE46190E1 (en) | 2007-09-28 | 2016-11-01 | Nippon Kayaku Kabushiki Kaisha | High-molecular weight conjugate of steroids |
US8703878B2 (en) | 2007-09-28 | 2014-04-22 | Nippon Kayaku Kabushiki Kaisha | High-molecular weight conjugate of steroids |
US8920788B2 (en) | 2008-03-18 | 2014-12-30 | Nippon Kayaku Kabushiki Kaisha | High-molecular weight conjugate of physiologically active substances |
WO2009116509A1 (ja) * | 2008-03-18 | 2009-09-24 | 日本化薬株式会社 | 生理活性物質の高分子結合体 |
JP5687899B2 (ja) * | 2008-03-18 | 2015-03-25 | 日本化薬株式会社 | 生理活性物質の高分子結合体 |
JPWO2009116509A1 (ja) * | 2008-03-18 | 2011-07-21 | 日本化薬株式会社 | 生理活性物質の高分子結合体 |
US9149540B2 (en) | 2008-05-08 | 2015-10-06 | Nippon Kayaku Kabushiki Kaisha | Polymer conjugate of folic acid or folic acid derivative |
US8808749B2 (en) | 2009-05-15 | 2014-08-19 | Nippon Kayaku Kabushiki Kaisha | Polymer conjugate of bioactive substance having hydroxy group |
JP2017132819A (ja) * | 2009-10-30 | 2017-08-03 | 興和株式会社 | ロキソプロフェン又はその塩含有の医薬組成物 |
JP2015166394A (ja) * | 2009-10-30 | 2015-09-24 | 興和株式会社 | ロキソプロフェン又はその塩含有の医薬組成物 |
JP2015172057A (ja) * | 2010-01-25 | 2015-10-01 | ローム アンド ハース エレクトロニック マテリアルズ エルエルシーRohm and Haas Electronic Materials LLC | 窒素含有化合物を含むフォトレジスト |
US9018323B2 (en) | 2010-11-17 | 2015-04-28 | Nippon Kayaku Kabushiki Kaisha | Polymer derivative of cytidine metabolic antagonist |
US9346923B2 (en) | 2011-09-11 | 2016-05-24 | Nippon Kayaku Kabushiki Kaisha | Method for manufacturing block copolymer |
JP2016156029A (ja) * | 2013-07-10 | 2016-09-01 | 生化学工業株式会社 | グリコサミノグリカン誘導体 |
JPWO2015005458A1 (ja) * | 2013-07-10 | 2017-03-02 | 生化学工業株式会社 | グリコサミノグリカン誘導体及びその製造方法 |
WO2015005458A1 (ja) * | 2013-07-10 | 2015-01-15 | 生化学工業株式会社 | グリコサミノグリカン誘導体及びその製造方法 |
US10675354B2 (en) | 2013-07-10 | 2020-06-09 | Seikagaku Corporation | Glycosaminoglycan derivative and method for producing same |
JP2019059951A (ja) * | 2013-07-10 | 2019-04-18 | 生化学工業株式会社 | グリコサミノグリカン誘導体及びその製造方法 |
US10098962B2 (en) | 2013-07-10 | 2018-10-16 | Seikagaku Corporation | Glycosaminoglycan derivative and method for producing same |
JP2016529362A (ja) * | 2013-08-29 | 2016-09-23 | ホーリー ストーン バイオテック カンパニー リミテッド | グリコサミノグリカン化合物、その調製方法および使用 |
JP6026708B1 (ja) * | 2015-01-09 | 2016-11-16 | 生化学工業株式会社 | コンドロイチン硫酸誘導体及び膀胱疾患処置剤 |
JP6489672B2 (ja) * | 2017-03-14 | 2019-03-27 | 生化学工業株式会社 | 関節疾患処置用組成物およびこれを含むキット |
JP7196019B2 (ja) | 2017-03-14 | 2022-12-26 | 生化学工業株式会社 | 関節疾患処置用組成物およびこれを含むキット |
WO2018168920A1 (ja) | 2017-03-14 | 2018-09-20 | 生化学工業株式会社 | 関節疾患処置用組成物およびこれを含むキット |
JP2019112423A (ja) * | 2017-03-14 | 2019-07-11 | 生化学工業株式会社 | 関節疾患処置用組成物およびこれを含むキット |
EP4389218A2 (en) | 2017-03-14 | 2024-06-26 | Seikagaku Corporation | Composition for treating joint disease and kit containing same |
KR20190111142A (ko) | 2017-03-14 | 2019-10-01 | 세이가가쿠 고교 가부시키가이샤 | 관절 질환 처치용 조성물 및 그것을 포함하는 키트 |
KR20230173746A (ko) | 2017-03-14 | 2023-12-27 | 세이가가쿠 고교 가부시키가이샤 | 관절 질환 처치용 조성물 및 그것을 포함하는 키트 |
JP2019167380A (ja) * | 2017-03-14 | 2019-10-03 | 生化学工業株式会社 | 関節疾患処置用組成物およびこれを含むキット |
CN110381959A (zh) * | 2017-03-14 | 2019-10-25 | 生化学工业株式会社 | 关节疾病处置用组合物及含有其的试剂盒 |
KR20190124240A (ko) | 2017-03-14 | 2019-11-04 | 세이가가쿠 고교 가부시키가이샤 | 관절 질환 처치용 조성물 및 그것을 포함하는 키트 |
JPWO2018168921A1 (ja) * | 2017-03-14 | 2020-01-16 | 生化学工業株式会社 | 関節疾患処置用組成物およびこれを含むキット |
JP7382474B2 (ja) | 2017-03-14 | 2023-11-16 | 生化学工業株式会社 | 関節疾患処置用組成物およびこれを含むキット |
US11738040B2 (en) | 2017-03-14 | 2023-08-29 | Seikagaku Corporation | Composition for treating joint disease and kit containing same |
WO2018168921A1 (ja) | 2017-03-14 | 2018-09-20 | 生化学工業株式会社 | 関節疾患処置用組成物およびこれを含むキット |
JPWO2018168920A1 (ja) * | 2017-03-14 | 2019-03-28 | 生化学工業株式会社 | 関節疾患処置用組成物およびこれを含むキット |
KR20200113036A (ko) | 2017-03-14 | 2020-10-05 | 세이가가쿠 고교 가부시키가이샤 | 관절 질환 처치용 조성물 및 그것을 포함하는 키트 |
US10835554B2 (en) | 2017-03-14 | 2020-11-17 | Seikagaku Corporation | Composition for treating joint disease and kit containing same |
KR20220031748A (ko) | 2017-03-14 | 2022-03-11 | 세이가가쿠 고교 가부시키가이샤 | 관절 질환 처치용 조성물 및 그것을 포함하는 키트 |
US10925839B2 (en) | 2017-03-14 | 2021-02-23 | Seikagaku Corporation | Composition for treating joint disease and kit containing same |
US11229666B2 (en) | 2017-03-14 | 2022-01-25 | Seikagaku Corporation | Composition for treating joint disease and kit containing same |
JP7404228B2 (ja) | 2018-03-22 | 2023-12-25 | 持田製薬株式会社 | 非ステロイド性抗炎症性化合物結合アルギン酸誘導体 |
JPWO2019182015A1 (ja) * | 2018-03-22 | 2021-03-11 | 持田製薬株式会社 | 非ステロイド性抗炎症性化合物結合アルギン酸誘導体 |
WO2019182015A1 (ja) | 2018-03-22 | 2019-09-26 | 持田製薬株式会社 | 非ステロイド性抗炎症性化合物結合アルギン酸誘導体 |
KR20200135964A (ko) | 2018-03-27 | 2020-12-04 | 세이가가쿠 고교 가부시키가이샤 | 히알루론산 합성 촉진제, 히알루론산 합성 촉진 방법, 및 세포평가 방법 |
JPWO2019189073A1 (ja) * | 2018-03-27 | 2020-05-28 | 生化学工業株式会社 | ヒアルロン酸合成促進剤、ヒアルロン酸合成促進方法、および細胞評価方法 |
WO2019189073A1 (ja) * | 2018-03-27 | 2019-10-03 | 生化学工業株式会社 | ヒアルロン酸合成促進剤、ヒアルロン酸合成促進方法、および細胞評価方法 |
KR20210093256A (ko) | 2018-11-16 | 2021-07-27 | 세이가가쿠 고교 가부시키가이샤 | 의약 조성물 |
JP6718567B1 (ja) * | 2018-11-16 | 2020-07-08 | 生化学工業株式会社 | 医薬組成物 |
US11744899B2 (en) | 2018-11-16 | 2023-09-05 | Seikagaku Corporation | Pharmaceutical composition containing a hyaluronic acid derivative |
WO2020101013A1 (ja) | 2018-11-16 | 2020-05-22 | 生化学工業株式会社 | 医薬組成物 |
TWI840445B (zh) | 2018-11-16 | 2024-05-01 | 日商生化學工業股份有限公司 | 水性組成物及其用途、注射套組、醫藥組成物及其製造方法、生成抑制方法 |
WO2021060395A1 (ja) * | 2019-09-25 | 2021-04-01 | 持田製薬株式会社 | 徐放性医薬組成物 |
WO2021060351A1 (ja) * | 2019-09-25 | 2021-04-01 | 持田製薬株式会社 | NSAIDs結合アルギン酸誘導体 |
Also Published As
Publication number | Publication date |
---|---|
EP2497785B1 (en) | 2018-09-12 |
US20110083991A1 (en) | 2011-04-14 |
CA2750725A1 (en) | 2005-07-21 |
EP2754454A2 (en) | 2014-07-16 |
JP4792294B2 (ja) | 2011-10-12 |
CN1930190A (zh) | 2007-03-14 |
JPWO2005066214A1 (ja) | 2007-07-26 |
KR20070031274A (ko) | 2007-03-19 |
HK1103549A1 (en) | 2007-12-21 |
NZ549010A (en) | 2010-07-30 |
RU2006128737A (ru) | 2008-02-20 |
CA2555759C (en) | 2012-04-17 |
EP2497785A2 (en) | 2012-09-12 |
EP2497785A3 (en) | 2013-04-03 |
US7879817B2 (en) | 2011-02-01 |
CA2555759A1 (en) | 2005-07-21 |
EP3363463A3 (en) | 2018-10-31 |
EP1710257A1 (en) | 2006-10-11 |
CA2750725C (en) | 2014-10-21 |
CN101921347B (zh) | 2014-07-30 |
HK1152055A1 (en) | 2012-02-17 |
RU2390529C2 (ru) | 2010-05-27 |
EP3363463A2 (en) | 2018-08-22 |
AU2005203988A1 (en) | 2005-07-21 |
KR101142583B1 (ko) | 2012-05-11 |
EP1710257A4 (en) | 2011-03-23 |
US20080221062A1 (en) | 2008-09-11 |
AU2005203988B2 (en) | 2010-11-11 |
CN101921347A (zh) | 2010-12-22 |
EP2754454A3 (en) | 2014-09-24 |
CN1930190B (zh) | 2011-04-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2005066214A1 (ja) | ヒアルロン酸誘導体及びそれを含む薬剤 | |
CA2695504C (en) | Compositions and methods for treatment and prevention of osteoarthritis | |
JP6417488B2 (ja) | 疼痛抑制用医薬組成物 | |
US11738040B2 (en) | Composition for treating joint disease and kit containing same | |
US20220031797A1 (en) | Pharmaceutical compositions containing hyaluronic acid and carnosine and relative use | |
US10925839B2 (en) | Composition for treating joint disease and kit containing same | |
EA042176B1 (ru) | Фармацевтические композиции, содержащие гиалуроновую кислоту и карнозин, и их соответствующее применение |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2005516899 Country of ref document: JP |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 12006501524 Country of ref document: PH Ref document number: 2555759 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2005703390 Country of ref document: EP Ref document number: 1020067015909 Country of ref document: KR Ref document number: 2006128737 Country of ref document: RU Ref document number: 549010 Country of ref document: NZ Ref document number: 2005203988 Country of ref document: AU |
|
ENP | Entry into the national phase |
Ref document number: 2005203988 Country of ref document: AU Date of ref document: 20050107 Kind code of ref document: A |
|
WWP | Wipo information: published in national office |
Ref document number: 2005203988 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 200580007323.2 Country of ref document: CN |
|
WWP | Wipo information: published in national office |
Ref document number: 2005703390 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 1020067015909 Country of ref document: KR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 10585417 Country of ref document: US |